<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0701256540
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1984
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        RETROVIR CAPS 100MG
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ZIDOVUDINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Tablet Container
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        549.20
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Delpharm Pozna&#x144; Sp&#xF3;&#x142;ka Akcyjna" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Delpharm Poznań Spółka Akcyjna
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Glaxo Saudi Arabia Ltd
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J05AF01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>RETROVIR is used to treat HIV (human immunodeficiency virus) infection</strong>.</p><p>The active ingredient in RETROVIR is zidovudine. RETROVIR is a type of medicine known as an anti-retroviral. It belongs to a group of medicines called NRTIs<em> (nucleoside analogue reverse transcriptase inhibitors)</em>.</p><p>RETROVIR does not cure HIV infection; it reduces the amount of virus in your body, and keeps it at a low level. RETROVIR also increases the <em>CD4 cell count</em> in your blood. CD4 cells are white blood cells that are important in helping your body to fight infection.</p><p>RETROVIR is used, in combination with other medicines (&lsquo;combination therapy&rsquo;), to treat HIV in adults and children. To control your HIV infection, and to stop your illness getting worse, you must keep taking all your medicines.</p><p>If you&rsquo;re pregnant, your doctor may want you to take RETROVIR, to help prevent you passing HIV on to your unborn baby. After the birth, your baby may be given RETROVIR to help prevent HIV infection.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Don&rsquo;t take RETROVIR:</strong><!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_4d7b0b7f-88ed-44cc-8a37-b98d1dc8d7f0 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;&nbsp;&nbsp; <strong>if you&rsquo;re allergic </strong>(<em>hypersensitive</em>)<strong> to zidovudine or any of the other ingredients of RETROVIR (listed in Section 6)</strong></p><p>&nbsp;&nbsp;&nbsp; <strong>if you have a very low white blood cell count<em> (</em></strong><em>neutropenia</em><strong><em>) </em></strong><strong>or a very low red blood cell count </strong>(<em>anaemia</em>).</p><p>&egrave; If you think any of these apply to you, <strong>don&rsquo;t take RETROVIR </strong>until you have checked with your doctor.</p><p><strong>Retrovir for new-born babies</strong></p><p>Retrovir must not be given to some new-born babies with liver problems, including:</p><p>&nbsp; some cases of hyper bilirubinaemia (increased amounts in the blood of a substance called bilirubin which may make the skin appear yellow)</p><p>&nbsp; other problems which cause high levels of liver enzymes in the blood.</p><p><strong>Ta</strong><strong>ke special care with Retrovir</strong></p><p>Some people taking Retrovir or combination therapy for HIV are more at risk of serious side effects. You need to be aware of the extra risks:</p><p>&nbsp; <strong>if you have ever had liver disease</strong> (including hepatitis B or C)</p><p>&nbsp; <strong>if you&rsquo;re seriously overweight</strong> (especially if you&rsquo;re a woman)</p><p>&egrave; <strong>Talk to your doctor if any of these applies to you</strong>. You may need extra check-ups, including blood tests, while you&rsquo;re taking your medication. See Section 4 for more information.</p><p><strong>Look out for important symptoms</strong><!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_104bfd3c-4968-4f02-8c9b-f300b8ee0f96 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Some people taking medicines for HIV infection develop other conditions, which can be serious. You need to know about important signs and symptoms to look out for while you&rsquo;re taking RETROVIR.</p><p><strong>Read the information on other possible side effects in Section 4 of this leaflet</strong>. If you have any questions about this information or the advice given:</p><p>&egrave; <strong>Talk to your doctor</strong>.</p><p><strong>Other medicines and RETROVIR</strong><!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_3d99358b-e2b8-475d-a935-5d9ea710c958 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Tell your doctor or pharmacist if you&rsquo;re taking any other medicines, if you&rsquo;ve taken any recently, or if you start taking new ones. This includes herbal medicines or other medicines bought without a prescription.</p><p><strong>Don&rsquo;t take these medicines with Retrovir:</strong></p><p>&nbsp; <strong>stavudine,</strong> used to treat HIV infection</p><p>&nbsp; <strong>ribavirin</strong> or injections of ganciclovir to treat viral infections</p><p>&nbsp; <strong>rifampicin</strong>, which is an antibiotic.</p><p>&egrave; <strong>Check with your doctor</strong> if you&rsquo;re taking these medicines.</p><p>&nbsp;</p><p><strong>Some medicines can make it more likely that you&rsquo;ll have side effects, or make side effects worse</strong></p><p>These include:</p><p>&nbsp; <strong>ribavirin</strong>, used to treat <strong>hepatitis C</strong></p><p>&nbsp; <strong>ganciclovir</strong> or <strong>interferon</strong>, used to treat <strong>virus infections</strong></p><p>&nbsp; <strong>pyrimethamine</strong>, used to treat <strong>malaria</strong> and other parasitic infections</p><p>&nbsp; <strong>dapsone</strong>, used to prevent <strong>pneumonia</strong> and treat <strong>skin infections</strong></p><p>&nbsp; <strong>flucytosine</strong>, used to treat <strong>fungal infections</strong> such as <strong>candida</strong></p><p>&nbsp; <strong>atovaquone</strong>, used to treat parasitic infections such as <strong>PCP</strong></p><p>&nbsp; <strong>amphotericin</strong> or <strong>co-trimoxazole</strong>, used to treat <strong>fungal and bacterial infections</strong></p><p>&nbsp; <strong>probenecid</strong>, used to treat <strong>gout</strong> and similar conditions, and given with some antibiotics to make them more effective</p><p>&nbsp; <strong>methadone</strong>, used as a <strong>heroin substitute</strong></p><p>&nbsp; <strong>vincristine</strong>, <strong>vinblastine</strong> or <strong>doxorubicin</strong>, used to treat <strong>cancer</strong>.</p><p>&egrave; <strong>Tell your doctor</strong> if you&rsquo;re taking any of these.</p><p><em>&nbsp;</em></p><p><strong>Some medicines interact with RETROVIR</strong><!--[if supportFields]><span
style='font-size:11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:
major-bidi;mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_27fc254f-2747-4d26-b313-3c50fe826d9e \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:
major-bidi;mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>These include:</p><p>&nbsp; <strong>rifampicin </strong>and<strong> clarithromycin</strong>, which are <strong>antibiotics</strong></p><p>&nbsp; <strong>phenytoin</strong>, used for treating <strong>epilepsy</strong></p><p>&nbsp; <strong>aspirin, codeine, </strong>or <strong>morphine</strong>, used for <strong>pain relief</strong></p><p>&nbsp; <strong>indomethacin,</strong> <strong>ketoprofen</strong> or <strong>naproxen,</strong> used for <strong>pain relief </strong>and <strong>inflammation</strong></p><p>&nbsp; <strong>oxazepam</strong> or <strong>lorazepam</strong>, used to treat <strong>anxiety</strong>, or to <strong>aid sleep</strong></p><p>&nbsp; <strong>cimetidine</strong>, used to treat <strong>ulcers</strong></p><p>&nbsp; <strong>clofibrate</strong>, used to reduce <strong>high cholesterol</strong></p><p>&nbsp; <strong>isoprinosine</strong>, used to treat <strong>virus infections</strong></p><p>&egrave; <strong>Tell your doctor</strong> if you&rsquo;re taking any of these medicines. Your doctor may need to monitor you while you&rsquo;re taking RETROVIR.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong><!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_2e0279a9-071f-4f5e-92b2-3775de27f780 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>If pregnant women who are HIV-positive take RETROVIR, they are less likely to pass the HIV infection on to their unborn babies. In some cases HIV infection may be passed on to unborn babies even if RETROVIR is used.</p><p>RETROVIR and similar medicines may cause side effects in unborn babies; which won&rsquo;t show up until after the baby has been born. However, this does not affect the recommendation to use RETROVIR to help protect your baby from getting HIV.</p><p>If you are pregnant, if you become pregnant, or if you&rsquo;re planning to become pregnant:</p><p>&egrave; <strong>Talk to your doctor</strong> about the risks and benefits of taking RETROVIR.</p><p><strong>Where possible, women who are HIV-positive should not breast feed</strong>, because HIV infection can be passed on to the baby in breast milk.&nbsp; If formula feeding is not possible, you should get advice from your doctor.</p><p>A small amount of the ingredients in RETROVIR can also pass into your breast-milk.</p><p>If you&rsquo;re breast feeding, or thinking about breast feeding:</p><p>&egrave; <strong>Talk to your doctor immediately</strong>.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong><!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_0c4ba5fd-7bbf-4f28-ac2a-51d31e300906 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p><strong>RETROVIR can make you dizzy</strong> and have other side effects that may make you less alert.</p><p>&egrave; <strong>Don&rsquo;t drive or operate machinery</strong> unless you&rsquo;re feeling well.</p><p>&nbsp;</p><p><strong>While you&rsquo;re taking RETROVIR<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_f08b1848-4f0c-47ac-a57f-690a02b4e6a6 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;</strong><!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p><strong>You will need regular blood tests</strong></p><p>For as long as you&rsquo;re taking RETROVIR, your doctor will arrange regular blood tests to check for side effects.</p><p><strong>Stay in regular contact with your doctor</strong></p><p>RETROVIR helps to control your condition, but it is not a cure for HIV infection. You need to keep taking it every day to stop your illness getting worse. Because RETROVIR does not cure HIV infection, you may still develop other infections and illnesses linked to HIV infection.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Always take RETROVIR exactly as your doctor has told you to</strong>. Check with your doctor or pharmacist if you&rsquo;re not sure.</p><p><strong>How much to take</strong><!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_50e02514-773e-4e28-b586-e32252b0780a \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p><strong>Adults and adolescents weighing at least 30&nbsp;kg</strong></p><p>The usual dose of RETROVIR is 250 or 300&nbsp;mg twice a day. Take each dose 12 hours apart.</p><p><strong>Children weighing at least 8&nbsp;kg and less than 14&nbsp;kg</strong></p><p>The usual dose of RETROVIR is one 100&nbsp;mg capsule twice a day. Take each dose 12 hours apart.</p><p><strong>Children weighing at least 14&nbsp;kg and less than 21&nbsp;kg</strong></p><p>The usual dose of RETROVIR is one 100&nbsp;mg capsule taken in the morning and two 100&nbsp;mg capsules taken in the evening.</p><p><strong>Children weighing more than 21&nbsp;kg and less than 30&nbsp;kg</strong></p><p>The usual dose of RETROVIR is two 100&nbsp;mg capsules twice a day. Take each dose 12 hours apart.</p><p>Capsules are not suitable for babies weighing less than 4&nbsp;kg. Your doctor may decide to give your baby liquid RETROVIR, or to give RETROVIR by injection instead.</p><p>&nbsp;</p><p><strong>Pregnancy, childbirth and new born babies:</strong></p><p>You should not normally take Retrovir during the first 14 weeks of your pregnancy. After week 14, the usual dose is 500 mg each day given as one 100 mg capsule five times per day until you start to go into labour. Your new-born baby may also be given Retrovir to help prevent it from getting infected with HIV.</p><p><strong>&nbsp;</strong></p><p><strong>People with kidney or liver problems </strong></p><p>If you have severe kidney or liver problems, you may be given a lower dose of RETROVIR, depending on how well your kidneys or liver are working. Follow your doctor&rsquo;s advice.</p><p><strong>How to take RETROVIR</strong><!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_57608373-6af1-4417-9f88-2f8dd622fc72 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Swallow the capsules whole, with some water.&nbsp; If you can&rsquo;t swallow the capsules whole, open the capsule and add the powder inside to a small amount of semi-solid food or liquid. You must eat or drink this straight away.</p><p><strong>If you forget to take RETROVIR</strong><!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_ede0ec54-aa1c-459e-ad0a-1c97560df9fc \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>If you forget to take a dose, just take your next dose at the usual time. <strong>Don&rsquo;t take a double dose to make up for a missed dose.</strong></p><p><strong>If you take too much RETROVIR<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_8ec986ee-f4f6-4691-a52f-34dbbc91bd5a \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;</strong><!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>If you take too much RETROVIR, contact your doctor or pharmacist for advice. If possible, show them the <strong>RETROVIR</strong> pack.</p><p><strong>Don&rsquo;t stop taking RETROVIR without advice</strong><!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_073d53b9-4af3-4a55-83ed-a1302131029e \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Take RETROVIR for as long as your doctor recommends. Don&rsquo;t stop unless your doctor advises you to.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, RETROVIR can cause side effects, but not everyone gets them. Some side effects may only be seen in your blood tests, and may not appear until 4 to 6&nbsp;weeks after you start taking RETROVIR. If you get any of these effects, and if they are severe, your doctor may advise you to stop taking RETROVIR.</p><p><strong>As well as the effects listed below</strong>, other conditions can develop during combination therapy for HIV.</p><p>&egrave; <strong>It is important to read the information </strong>in &lsquo;<em>Other possible side effects of combination therapy for HIV&rsquo;</em>, later in this section.</p><p><strong>Very common side effects</strong><!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_11059407-9c2a-4a6f-bb24-3c73c7d551f0 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>These may affect <strong>more than 1 in 10</strong> people:</p><p>&nbsp; headaches</p><p>&nbsp; feeling sick (nausea).</p><p><strong>Common side effects</strong><!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_d2c2606a-ae4a-4872-9482-5bd601492b76 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>These may affect <strong>up to 1 in 10</strong> people:</p><p>&nbsp; being sick (vomiting)</p><p>&nbsp; diarrhoea</p><p>&nbsp; stomach pains</p><p>&nbsp; generally feeling unwell (<em>malaise</em>)</p><p>&nbsp; feeling dizzy</p><p>&nbsp; aching muscles.</p><p>Common side effects that may show up in your blood tests are:</p><p>&nbsp; a low red blood cell count <em>(anaemia)</em> or low white blood cell count <em>(neutropenia or leucopenia)</em></p><p>&nbsp; an increase in the level of liver enzymes</p><p>&nbsp; an increase in lactic acid&nbsp;</p><p>&nbsp; an increased amount of <em>bilirubin</em> (a substance produced in the liver).</p><p><strong>Uncommon side effects</strong><!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_c89f8fd5-40dd-4bd4-b2bf-0fd58e251795 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>These may affect <strong>up to 1 in 100</strong> people:</p><p>&nbsp; skin rash (red, raised or itchy skin)</p><p>&nbsp; feeling breathless</p><p>&nbsp; fever (high temperature)</p><p>&nbsp; general aches and pains</p><p>&nbsp; wind (flatulence)</p><p>&nbsp; weakness.</p><p>Uncommon side effects that may show up in your blood tests are:</p><p>&nbsp; a decrease in the number of cells involved in blood clotting <em>(thrombocytopenia)</em>, or in all kinds of blood cells <em>(pancytopenia)</em>.</p><p><strong>Rare side effects</strong><!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_99b7d979-397f-4e52-b4f4-304af25259b9 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>These may affect <strong>up to 1 in 1000</strong> people:</p><p>&nbsp; liver disorders, such as an enlarged liver or fatty liver</p><p>&nbsp; lactic acidosis (see section &lsquo;<em>Other possible side effects of combination therapy for HIV&rsquo;) </em></p><p>&nbsp; inflammation of the pancreas</p><p>&nbsp; chest pain; disease of the heart muscle</p><p>&nbsp; fits (convulsions)</p><p>&nbsp; feeling depressed or anxious; not being able to sleep (insomnia); not being able to concentrate; feeling drowsy</p><p>&nbsp; indigestion; loss of appetite; taste disturbance</p><p>&nbsp; changes in the colour of the nails, skin, or the skin inside the mouth</p><p>&nbsp; a flu-like feeling &mdash; chills, sweating and cough</p><p>&nbsp; tingly feelings in the skin (pins and needles)</p><p>&nbsp; passing urine more often</p><p>&nbsp; enlarged breasts in men.</p><p>A rare side effect that may show up in your blood tests is:</p><p>&nbsp; reduction in the number of red blood cell <em>(pure red cell aplasia)</em>.</p><p><strong>Very rare side effects</strong><!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_7c14bee1-ab30-4844-ac56-4327349bb186 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>These may affect <strong>up to 1 in 10,000</strong> people:</p><p>A very rare side effect that may show up in blood tests:</p><p>&nbsp; failure of the bone marrow to produce new blood cells <em>(aplastic anaemia)</em>.</p><p><strong>If you get side effects</strong><!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_3c11565f-7359-4d9e-8915-86d812276fc6 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>&egrave; <strong>Tell your doctor or pharmacist</strong> if any of the side effects gets <strong>severe or troublesome</strong>, or if you notice any side effects not listed in this leaflet.</p><p>Other possible side effects of combination therapy for HIV<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_fffa4bb9-906f-4db8-ae10-1f6b43057b0e \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Some other conditions may develop during HIV treatment.</p><p><strong>Old infections may flare up</strong></p><p>People with advanced HIV infection (AIDS) have weak immune systems, and are more likely to develop serious infections <em>(opportunistic infections)</em>. When these people start treatment, they may find that old, hidden infections flare up, causing signs and symptoms of inflammation. These symptoms are probably caused by the body&rsquo;s immune system becoming stronger, so that the body starts to fight these infections.</p><p>If you get any symptoms of infection while you&rsquo;re taking RETROVIR:</p><p>&egrave; <strong>Tell your doctor immediately</strong>. Don&rsquo;t take other medicines for the infection without your doctor&rsquo;s advice.</p><p><strong>Your body shape may change</strong><!--[if supportFields]><span
style='font-size:11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:
major-bidi;mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_f2e87d88-adbf-4a01-85a2-21da583b62f4 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:
major-bidi;mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Treatment with RETROVIR or other medicines that contain zidovudine may cause a loss of fat from legs, arms and face (lipoatrophy). Your doctor should monitor for signs of lipoatrophy. Tell your doctor if you notice any loss of fat from your legs, arms, and face. When these signs occur, your doctor will assess if RETROVIR should be stopped and your HIV treatment changed. If you stop taking RETROVIR, it may take several months to see any lost fat return. You may not regain all of your lost body fat.</p><p><em>Other effects may show up in blood tests</em></p><p>&nbsp; Increased blood levels of sugar, fatty acids <em>(triglycerides)</em> and cholesterol may show up in blood tests.</p><p><strong>Lactic acidosis is a rare but serious side effect</strong></p><p>Some people taking RETROVIR, or other medicines like it (NRTIs), develop a condition called lactic acidosis, together with an enlarged liver. Lactic acidosis is caused by a build-up of lactic acid in the body. It is rare; if it happens, it usually develops after a few months of treatment. It can be life-threatening, causing failure of internal organs.</p><p>Lactic acidosis is more likely to develop in women and people who have liver disease.</p><p><strong>Signs of lactic acidosis include:</strong><!--[if supportFields]><span
style='font-size:11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:
major-bidi;mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_7fb5787c-6023-4952-bb59-4b26eec9bb50 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:
major-bidi;mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp; <strong>deep, rapid, difficult breathing</strong></p><p>&nbsp; <strong>weakness</strong> in the limbs</p><p>&nbsp; <strong>loss of appetite, sudden unexplained weight loss</strong></p><p>&nbsp; <strong>feeling sick</strong> (nausea), <strong>being sick</strong> (vomiting)</p><p>&nbsp; <strong>stomach pain.</strong></p><p>During your treatment, your doctor will monitor you for signs of lactic acidosis. If you have any of the symptoms listed above, or any other symptoms that worry you:</p><p>&egrave; <strong>See your doctor as soon as possible</strong>.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep RETROVIR out of the sight and reach of children.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Don&rsquo;t take RETROVIR after the expiry date shown on the carton.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store RETROVIR below 30&nbsp;&deg;C (86&nbsp;&deg;F).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep dry and protect from ligh</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is zidovudine.</p><p>The other ingredients are:</p><p>Starches, microcrystalline cellulose, sodium starch glycollate, magnesium stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                PVC/aluminium foil blister pack 

Not all pack sizes may be marketed.

RETROVIR is trademark owned by or licensed to the ViiV Healthcare group of companies.
© 2023 ViiV Healthcare group of companies. All rights reserved. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufactured by:</strong><!--[if supportFields]><span
style='font-size:11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:
major-bidi;mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_8d74d050-ce69-411b-9168-bd76276d1980 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:
major-bidi;mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Delpharm Poznań Sp&oacute;łka Akcyjna, ul. Grunwaldzka 189, 60-322 Poznań, Poland<!--[if supportFields]><span
style='font-size:11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:
major-bidi;mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_d881e4b9-a2f8-44e2-9f90-350589f48024 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:
major-bidi;mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p><strong>Marketing Authorization Holder:</strong><!--[if supportFields]><span
style='font-size:11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:
major-bidi;mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_3ad6d115-f8e5-4814-8b33-c6d588aac0ce \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:
major-bidi;mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Glaxo Saudi Arabia Ltd.* Jeddah, KSA.</p><p>Address: P.O. Box 22617 Jeddah 21416 &ndash; Kingdom of Saudi Arabia.</p><p><em>*member of the GlaxoSmithKline group of companies</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Version Number: GDS40 
Version Date: 27 May 2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>يُستخدم ريتروڤير لعلاج العدوى بفيروس نقص المناعة البشرية </strong><strong>(HIV)</strong><strong>.</strong></p><p dir="RTL">المادة الفعَّالة في ريتروڤير هي زيدوڤودين. يُعد ريتروڤير نوعًا من الأدوية المعروفة باسم مضادات الفيروسات الرجعية. وينتمي إلى فئة من الأدوية تُسمى <em>الأدوية النيوكليوزيدية المضادة لإنزيم المنتسخة المعاكس</em> <em>(NRTI)</em>.</p><p dir="RTL">لا يقضي ريتروڤير على عدوى فيروس نقص المناعة البشرية، وإنما يقلل من انتشار الفيروس في الجسم ويبقي مستوياته منخفضة. كما يعمل ريتروڤير على زيادة <em>عدد خلايا</em> <em>CD4</em> في الدم. وخلايا CD4 هي خلايا دم بيضاء لها دور مهم في مساعدة الجسم على مكافحة العدوى.</p><p dir="RTL">يُستخدم ريتروڤير مع مجموعة من الأدوية الأخرى (علاج مُرَكّب) لعلاج عدوى فيروس نقص المناعة البشري (HIV) لدى البالغين والأطفال. ويجب الاستمرار في تناول جميع الأدوية للسيطرة على عدوى فيروس نقص المناعة البشرية لمنع تفاقم المرض.</p><p dir="RTL">إذا كنتِ حاملاً، فربما يرى طبيِبك ضرورة تناول ريتروڤير، للمساعدة على منع انتقال الفيروس إلى الجنين. وبعد الولادة، يمكن إعطاء طفلك ريتروڤير للمساعدة على منع إصابته بفيروس نقص المناعة البشرية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول ريتروڤير:</strong><!--[if supportFields]><b><span style='mso-bidi-font-size:
12.0pt'><span style='mso-element:field-begin'></span></span></b><span dir=LTR></span><span
dir=LTR></span><b><span dir=LTR style='mso-bidi-font-size:12.0pt'><span
dir=LTR></span><span dir=LTR></span> DOCVARIABLE
VAULT_ND_b45753f7-44f0-4285-b9fa-5729d27f4eaf \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='mso-bidi-font-size:12.0pt'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>إذا كنت تعاني من الحساسية </strong><em>(فرط الحساسية)</em> <strong>لزيدوڤودين أو أي من مكونات ريتروڤير الأخرى (المدرجة في القسم </strong><strong>6</strong><strong>)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>في حالة الانخفاض الشديد في عدد خلايا الدم البيضاء</strong><em> (نقص العدلات)<strong> </strong></em><strong>أو في حالة الانخفاض الشديد في عدد خلايا الدم الحمراء</strong> <em>(فقر الدم)</em>.</p><p dir="RTL">&ccedil; إذا ظننت أن أيًا من هاتين الحالتين تنطبق عليك، <strong>امتنع عن تناول ريتروڤير</strong> إلى أن تستشير الطبيب.</p><p dir="RTL"><strong>ريتروڤير &rlm;</strong>‫<strong>للأطفال حديثي الولادة</strong><!--[if supportFields]><b><span
dir=LTR style='mso-bidi-font-size:12.0pt'><span style='mso-element:field-begin'></span>
DOCVARIABLE VAULT_ND_2119464e-af07-4ed1-bfb6-0f9a999d4121 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
dir=LTR style='mso-bidi-font-size:12.0pt'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">يجب عدم إعطاء ريتروڤير لبعض الأطفال حديثي الولادة الذين يعانون من مشاكل في الكبد، بما في ذلك:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض حالات فرط بيليروبين الدم (زيادة الكميات في الدم لمادة تسمى البيليروبين والتي قد تجعل الجلد يبدو أصفرًا).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل أخرى تسبب زيادة مستويات إنزيمات الكبد في الدم.</p><p dir="RTL"><strong>ينبغي توخي الحذر عند استخدام ريتروڤير</strong><!--[if supportFields]><b><span
style='mso-element:field-begin'></span></b><span dir=LTR></span><span dir=LTR></span><b><span
dir=LTR><span dir=LTR></span><span dir=LTR></span> DOCVARIABLE
VAULT_ND_e15a420e-ee8e-45bc-94d3-3be40e7f1829 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='mso-element:field-end'></span></b><![endif]--></p><p dir="RTL">بعض المرضى الذين يتناولون ريتروڤير أو أحد العلاجات المركبة لفيروس نقص المناعة البشرية يكونون أكثر عُرضة للإصابة بالآثار الجانبية الخطيرة. يجب أن تضع في اعتبارك المخاطر الأخرى التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا سبق لك في أي وقت الإصابة بأمراض الكبد</strong> (بما في ذلك إلتهاب الكبد الوبائي B أو C)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تعاني من البدانة المفرطة</strong> (على الأخص إذا كنتِ امرأة)</p><p dir="RTL">&ccedil; <strong>استشر طبيبك إذا كان أي مما سبق ينطبق عليك</strong>. قد تحتاج إلى مزيد من الفحوصات، بما في ذلك فحوصات الدم، أثناء تناول العلاج. انظر القسم 4 لمزيد من المعلومات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>انتبه لظهور الأعراض الخطيرة</strong><!--[if supportFields]><b><span
style='mso-bidi-font-size:12.0pt'><span style='mso-element:field-begin'></span></span></b><span
dir=LTR></span><span dir=LTR></span><b><span dir=LTR style='mso-bidi-font-size:
12.0pt'><span dir=LTR></span><span dir=LTR></span> DOCVARIABLE
VAULT_ND_b8580923-d958-40cd-a7f3-e9c71ceb250a \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='mso-bidi-font-size:12.0pt'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">تظهر على بعض الأشخاص الذين يتناولون أدوية لعلاج عدوى فيروس نقص المناعة البشرية بعض الأعراض الأخرى التي قد تكون خطيرة. يجب عليك معرفة العلامات والأعراض المهمة التي يجب الانتباه لها أثناء تناول ريتروڤير.</p><p dir="RTL"><strong>اقرأ المعلومات الخاصة بالآثار الجانبية الأخرى المحتملة في القسم 4 من هذه النشرة.</strong> إذا كان لديك أي أسئلة حول هذه المعلومات أو بشأن النصيحة التي حصلت عليها:</p><p dir="RTL"><strong>&ccedil;&nbsp;&nbsp;&nbsp; </strong><strong>تحدث إلى طبيبك.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وريتروڤير</strong><!--[if supportFields]><b><span style='mso-bidi-font-size:
12.0pt'><span style='mso-element:field-begin'></span></span></b><span dir=LTR></span><span
dir=LTR></span><b><span dir=LTR style='mso-bidi-font-size:12.0pt'><span
dir=LTR></span><span dir=LTR></span> DOCVARIABLE
VAULT_ND_6c3c7c6e-2ae7-4ed2-9091-b0823f209cda \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='mso-bidi-font-size:12.0pt'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">قم بإبلاغ الطبيب أو الصيدلاني إذا كنت تتناول أية أدوية أخرى، أو إذا كنت قد تناولت أية أدوية مؤخرًا أو عند الشروع في تناول أدوية جديدة. ويشمل هذا الأمر الأدوية العشبية أو الأدوية الأخرى التي تُشترى دون وصفة طبية.</p><p dir="RTL"><strong>لا ينصح بتناول هذه الأدوية مع ريتروڤير:</strong><!--[if supportFields]><b><span
lang=AR-SA style='mso-bidi-font-size:12.0pt'><span style='mso-element:field-begin'></span>
</span></b><b><span dir=LTR style='mso-bidi-font-size:12.0pt'>DOCVARIABLE</span></b><span
dir=RTL></span><span dir=RTL></span><b><span style='mso-bidi-font-size:12.0pt'><span
dir=RTL></span><span dir=RTL></span> </span></b><b><span dir=LTR
style='mso-bidi-font-size:12.0pt'>VAULT_ND_3fdaf50e-1448-420b-b293-772d85fd38da
\* MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='mso-bidi-font-size:12.0pt'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='mso-bidi-font-size:12.0pt'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ستاڤودين</strong>، المستخدم لعلاج فيروس نقص المناعة البشرية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ريباڤيرين</strong><strong> </strong>أو حقن جانسيكلوڤير المستخدم لعلاج العدوى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ريفامبسين</strong>،<strong> </strong>وهو من المضادات الحيوية</p><p dir="RTL">&ccedil;&nbsp; <strong>استشر طبيبك</strong> إذا كنت تتناول هذه الأدوية.</p><p dir="RTL"><strong>قد تزيد بعض الأدوية من احتمالية ظهور آثار جانبية أو جعلها أسوأ</strong></p><p dir="RTL">وتشمل تلك الأدوية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ريباڤيرين</strong>، المستخدم لعلاج <strong>التهاب الكبد الوبائي &quot;سي&quot;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>جانسيكلوڤير</strong> أو <strong>إنترفيرون</strong>، المستخدمين لعلاج <strong>العدوى الفيروسية</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>بيريميثامين،</strong> المستخدم لعلاج <strong>الملاريا</strong> والعدوى الطفيلية الأخرى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>دابسون</strong>، المستخدم لمنع <strong>الالتهاب الرئوي</strong> وعلاج <strong>حالات عدوى الجلد</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>فلوسيتوزين</strong>، المستخدم لعلاج <strong>العدوى الفطرية </strong>مثل المبيضات (<strong>الكانديدا</strong>)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>أتوڤاكون</strong>، المستخدم لعلاج العدوى الطفيلية مثل <strong>الالتهاب الرئوي بالمتكيسة الجؤجؤية </strong><strong>(PCP)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>أمفوتيريسين</strong> أو <strong>كوتريموكسازول</strong>، المستخدم لعلاج <strong>الإصابة بالعدوى الفطرية أو البكتيرية</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>بروبينسيد</strong>، المستخدم لعلاج <strong>النقرس</strong> والحالات المماثلة، ويوصف مع بعض المضادات الحيوية لجعل العلاج أكثر فعالية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ميثادون</strong>، المستخدم <strong>كبديل للهيروين </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ڤينكريستين</strong> أو <strong>ڤينبلاستين</strong> أو <strong>دوكسوروبيسين</strong> المستخدم لعلاج <strong>مرض السرطان</strong>.</p><p dir="RTL">&ccedil;&nbsp;&nbsp;&nbsp; <strong>ينبغي إخبار الطبيب أو الصيدلاني</strong> إذا كنت تتناول أيًا من هذه الأدوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تتفاعل بعض الأدوية مع ريتروڤير</strong></p><p dir="RTL">وتشمل تلك الأدوية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ريفامبيسين</strong> و<strong>كلاريثروميسين</strong>، وهما من<strong> المضادات الحيوية</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>فينيتوين</strong>، المستخدم لعلاج <strong>الصرع</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>أسبرين</strong> أو <strong>كودايين</strong> أو <strong>مورفين</strong>، المستخدم <strong>لتسكين الألم</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إندوميثاسين</strong> أو <strong>كيتوبروفين</strong> أو <strong>نابروكسين</strong>، المستخدم<strong> لتسكين الألم</strong> وعلاج <strong>الالتهاب</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>أوكسازيبام</strong> أو <strong>لورازيبام</strong>، المستخدم لعلاج <strong>القلق</strong>، أو <strong>للمساعدة على النوم</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>سيميتيدين</strong>، المستخدم لعلاج <strong>القرح</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>كلوفيبرات</strong>، المستخدم لخفض <strong>نسب الكوليسترول المرتفعة في الدم</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إيزوبرينوسين</strong>، المستخدم لعلاج <strong>العدوى الفيروسية</strong></p><p dir="RTL">&ccedil;&nbsp; <strong>ينبغي إخبار الطبيب</strong> إذا كنت تتناول أيًا من هذه الأدوية. ينبغي إطلاع الطبيب على حالتك أولاً بأول طوال فترة<br />تناول ريتروڤير.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong><!--[if supportFields]><b><span style='mso-bidi-font-size:
12.0pt'><span style='mso-element:field-begin'></span></span></b><span dir=LTR></span><span
dir=LTR></span><b><span dir=LTR style='mso-bidi-font-size:12.0pt'><span
dir=LTR></span><span dir=LTR></span> DOCVARIABLE
VAULT_ND_1cc61434-8a07-4969-ab7f-d144a6102f53 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='mso-bidi-font-size:12.0pt'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">إذا كانت النساء الحوامل المصابات بفيروس نقص المناعة البشرية يتناولن ريتروڤير، تقل احتمالية نقل العدوى بفيروس نقص المناعة البشرية إلى الأجنة. وفي بعض الحالات، قد تنتقل عدوى فيروس نقص المناعة البشرية إلى الأجنة حتى مع استخدام ريتروڤير.</p><p dir="RTL">قد يسبب ريتروڤير والأدوية المماثلة آثارًا جانبية في الأجنة. والتي لن تظهر إلا بعد ولادة الطفل. إلا أن هذا لا يؤثر على التوصية باستخدام ريتروڤير للمساعدة في حماية طفلك من الإصابة بفيروس نقص المناعة البشرية.</p><p dir="RTL">إذا &rlm;كنتِ حاملاً أو إذا أصبحتِ حاملاً أو إذا كنتِ تخططين للحمل:</p><p dir="RTL">&ccedil;&nbsp; <strong>تحدثي مع طبيبكِ</strong> حول مخاطر وفوائد تناول ريتروڤير.</p><p dir="RTL"><strong>يجب على الأمهات المصابات بفيروس نقص المناعة البشرية تجنب إرضاع أطفالهن رضاعة طبيعية إن أمكن،</strong> لأنه يمكن أن تنتقل عدوى فيروس نقص المناعة البشرية إلى الطفل عبر لبن الأم. في حال تعذر الرضاعة الصناعية، يجب استشارة الطبيب.</p><p dir="RTL">يمكن أن تنتقل كمية بسيطة من مكونات ريتروڤير إلى الطفل عبر لبن الأم.</p><p dir="RTL">إذا كنتِ ترضعين طفلك رضاعة طبيعية أو تفكرين في ذلك:</p><p dir="RTL"><strong>&ccedil;&nbsp; </strong><strong>تحدثي إلى طبيبك على الفور</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span style='mso-element:field-begin'></span></b><span
dir=LTR></span><span dir=LTR></span><span dir=LTR><span dir=LTR></span><span
dir=LTR></span> DOCVARIABLE VAULT_ND_a0de27ad-d950-4b73-b48d-f09cfc20ea76 \*
MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span style='mso-element:field-end'></span></b><![endif]--></p><p dir="RTL"><strong>يمكن أن يصيبك ريتروڤير بالدوار</strong> وغيره من الأعراض الجانبية التي تجعلك أقل انتباهًا.</p><p dir="RTL">&ccedil;&nbsp; <strong>تجنب القيادة أو تشغيل الماكينات</strong> ما لم تكن تشعر أنك على ما يرام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أثناء تناول ريتروڤير</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA><span style='mso-element:
field-begin'></span> </span></b><span dir=LTR>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><b style='mso-ansi-font-weight:normal'><span dir=RTL></span><span
dir=RTL></span> </b><span dir=LTR>VAULT_ND_001ab5b0-ee51-4bf8-bdb2-442cbca8e106
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p dir="RTL"><strong>سوف تحتاج إلى إجراء فحوصات دم دورية</strong></p><p dir="RTL">طوال مدة تناول ريتروڤير، سوف يرتّب الطبيب أمر إجراء فحوصات دم دورية للتحقق من الأعراض الجانبية.</p><p>&nbsp;</p><p dir="RTL"><strong>ابق على اتصال بالطبيب بشكل منتظم</strong></p><p dir="RTL">يساعد ريتروڤير على التحكم في حالتك، ولكنه ليس علاجًا لفيروس نقص المناعة البشرية. ويجب عليك تناوله يوميًا لمنع تفاقم المرض. ونظرًا لأن ريتروڤير ليس علاجًا لعدوى فيروس نقص المناعة البشرية، فقد تصاب بعدوى وأمراض أخرى ترتبط بعدوى فيروس نقص المناعة البشرية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ينبغي دائمًا استعمال ريتروڤير بدقة حسب إرشادات الطبيب.</strong> يجب استشارة الطبيب أو الصيدلاني في حالة الشك بشأن طريقة استعماله على الوجه الصحيح.</p><p dir="RTL"><strong>الجرعة</strong><!--[if supportFields]><b style='mso-ansi-font-weight:
normal'><span style='mso-element:field-begin'></span></b><span dir=LTR></span><span
dir=LTR></span><span dir=LTR><span dir=LTR></span><span dir=LTR></span>
DOCVARIABLE VAULT_ND_a1931c56-ece7-4b6f-abef-693a492edee5 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span style='mso-element:field-end'></span></b><![endif]--></p><p dir="RTL"><strong>البالغون والمراهقون الذين يبلغ وزنهم </strong><strong>30</strong><strong> كجم على الأقل</strong></p><p dir="RTL">الجرعة المعتادة من ريتروڤير هي 250 أو 300 ملجم مرتين في اليوم. تؤخذ الجرعة كل 12 ساعة.</p><p dir="RTL"><strong>الأطفال الذين لا يقل وزنهم عن </strong><strong>8</strong><strong> كجم ولا يزيد عن </strong><strong>14</strong><strong> كجم</strong></p><p dir="RTL">الجرعة المعتادة من ريتروڤير هي كبسولة واحدة 100 ملجم مرتين في اليوم. تؤخذ الجرعة كل 12 ساعة.</p><p dir="RTL"><strong>الأطفال الذين لا يقل وزنهم عن </strong><strong>14</strong><strong> كجم ولا يزيد عن </strong><strong>21</strong><strong> كجم</strong></p><p dir="RTL">الجرعة المعتادة من دواء ريتروڤير هي كبسولة واحدة 100 ملجم صباحًا وكبسولتين 100 ملجم مساءً.</p><p dir="RTL"><strong>الأطفال الذين يزيد وزنهم عن </strong><strong>21</strong><strong> كجم وأقل من </strong><strong>30</strong><strong> كجم</strong></p><p dir="RTL">الجرعة المعتادة من ريتروڤير هي كبسولتين 100 ملجم مرتين في اليوم. تؤخذ الجرعة كل 12 ساعة.</p><p dir="RTL">الكبسولات ليست مناسبة للأطفال الذين يقل وزنهم عن 4 كجم. ربما يقرر طبيبك بدلاً من ذلك إعطاء طفلك ريتروڤير شراب أو إعطاءه ريتروڤير عن طريق الحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والولادة والأطفال حديثي الولادة</strong><!--[if supportFields]><b style='mso-ansi-font-weight:
normal'><span style='font-style:normal;mso-ansi-font-style:italic'><span
style='mso-element:field-begin'></span></span></b><span dir=LTR></span><span
dir=LTR></span><span dir=LTR><span dir=LTR></span><span dir=LTR></span>
DOCVARIABLE VAULT_ND_532a7984-eba7-4f69-b44c-37b788624dc0 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span style='font-style:normal;mso-ansi-font-style:
italic'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">يجب عدم تناول <strong>ريتروڤير</strong> عادةً خلال أول 14 أسبوعًا من الحمل. وبعد الأسبوع 14، تكون الجرعة المعتادة 500 ملجم كل يوم تُعطى على شكل كبسولة 100 ملجم خمس مرات يوميًا حتى الولادة.&nbsp; يمكن أيضاً إعطاء طفلك حديث الولادة جرعة من ريتروڤير لحمايته من الإصابة بفيروس نقص المناعة البشري.</p><p dir="RTL"><strong>الأشخاص الذين يعانون من مشكلات في الكلى أو الكبد </strong></p><p dir="RTL">إذا كان لديك مشكلات خطيرة في الكلى أو الكبد، قد يتم إعطاؤك جرعة أقل من ريتروڤير، حسب كفاءة وظيفة الكليتين أو الكبد لديك. اتبع نصيحة طبيبك.</p><p dir="RTL"><strong>طريقة تناول الجرعة</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span style='mso-element:field-begin'></span></b><span
dir=LTR></span><span dir=LTR></span><span dir=LTR><span dir=LTR></span><span
dir=LTR></span> DOCVARIABLE VAULT_ND_16e2525e-c57c-4990-b73d-20af155b1b41 \*
MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span style='mso-element:field-end'></span></b><![endif]--></p><p dir="RTL">ابتلع الكبسولات كاملة مع بعض الماء. إذا كنت لا تستطيع ابتلاع الكبسولات كاملة، يمكنك فتح الكبسولة وإضافة المسحوق على كمية صغيرة من الطعام متوسط الصلابة أو السائل. ويجب أكله أو شربه على الفور.</p><p dir="RTL"><strong>في حالة نسيان تناول ريتروڤير</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span style='mso-element:field-begin'></span></b><span
dir=LTR></span><span dir=LTR></span><span dir=LTR><span dir=LTR></span><span
dir=LTR></span> DOCVARIABLE VAULT_ND_7021e713-41a8-4ee1-b516-177740e074c6 \*
MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span style='mso-element:field-end'></span></b><![endif]--></p><p dir="RTL">في حالة نسيان تناول إحدى الجرعات، فقط تناول الجرعة التالية في الموعد المعتاد. <strong>لا تتناول جرعة مضاعفة لتعويض الجرعة التي فاتتك</strong>.</p><p dir="RTL"><strong>في حال تناول جرعة زائدة من ريتروڤير</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span style='mso-element:field-begin'></span></b><span
dir=LTR></span><span dir=LTR></span><span dir=LTR><span dir=LTR></span><span
dir=LTR></span> DOCVARIABLE VAULT_ND_09e1a224-6bad-47ad-a797-eb42543cd018 \*
MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span style='mso-element:field-end'></span></b><![endif]--></p><p dir="RTL">إذا تناولت جرعة زائدة من ريتروڤير، فأستشر الطبيب أو الصيدلي المختص. إذا أمكن، أظهر لهم عبوة <strong>ريتروڤير</strong>.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>لا تتوقف عن تناول ريتروڤير دون استشارة الطبيب المختص</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span style='mso-element:field-begin'></span></b><span
dir=LTR></span><span dir=LTR></span><span dir=LTR><span dir=LTR></span><span
dir=LTR></span> DOCVARIABLE VAULT_ND_3c7ce048-d3fa-4a0d-9159-79263461c2a2 \*
MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span style='mso-element:field-end'></span></b><![endif]--></p><p dir="RTL">تناول ريتروڤير للفترة التي حددها الطبيب. لا تتوقف عن تناول الدواء ما لم ينصحك الطبيب بهذا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يتسبب ريتروڤير في حدوث بعض الآثار الجانبية، لكن ليس بالضرورة أن يصاب جميع الأشخاص بهذه الأعراض. قد تظهر بعض الأعراض الجانبية في فحوصات الدم فقط، وقد لا تظهر إلا بعد مرور 4 إلى 6 أسابيع من تناول ريتروڤير. عند الإصابة بأي من هذه الأعراض، وإذا كانت حادة، عندئذ قد ينصحك الطبيب بالتوقف عن تناول ريتروڤير.</p><p dir="RTL"><strong>إلى جانب الآثار الجانبية المذكورة أدناه، </strong>يمكن أن تظهر بعض الحالات الأخرى أثناء العلاج المركب لفيروس نقص المناعة البشرية.</p><p dir="RTL">&ccedil;&nbsp; <strong>من المهم قراءة المعلومات الموجودة</strong> في <em>&quot;الآثار الجانبية الأخرى المحتملة للعلاج المركب لفيروس نقص المناعة البشرية&quot;</em>، لاحقًا في هذا القسم.</p><p dir="RTL"><strong>الآثار الجانبية الشائعة جدًا</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span style='mso-element:field-begin'></span></b><span
dir=LTR></span><span dir=LTR></span><span dir=LTR><span dir=LTR></span><span
dir=LTR></span> DOCVARIABLE VAULT_ND_2c1f3b09-b76d-4430-b6a0-5f3a8fbd62e2 \*
MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span style='mso-element:field-end'></span></b><![endif]--></p><p dir="RTL">قد تصيب <strong>أكثر من شخص واحد من كل 10</strong> أشخاص:</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتوعك (الغثيان)</p><p dir="RTL"><strong>الآثار الجانبية الشائعة</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span style='mso-element:field-begin'></span></b><span
dir=LTR></span><span dir=LTR></span><span dir=LTR><span dir=LTR></span><span
dir=LTR></span> DOCVARIABLE VAULT_ND_fbfa2909-8f98-461d-878a-874011ab0662 \*
MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span style='mso-element:field-end'></span></b><![endif]--></p><p dir="RTL">قد تصيب <strong>حتى شخص واحد من كل </strong><strong>10</strong> أشخاص:</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإعياء (القيء)</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام المعدة</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور العام بعدم الراحة &nbsp;<em>(التوعك)</em></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدوار</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام العضلات</p><p dir="RTL">من بين الآثار الجانبية الشائعة التي قد تظهر في فحوصات الدم:</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد خلايا الدم الحمراء <em>(فقر الدم)</em> أو انخفاض في عدد خلايا الدم البيضاء <em>(نقص العدلات أو قلة الكريات البيض)</em></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في مستوى إنزيمات الكبد</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في حمض اللاكتيك</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في كمية <em>البيليروبين </em>(مادة تُنتج في الكبد)</p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة</strong></p><p dir="RTL">قد تصيب <strong>حتى شخص واحد من كل </strong><strong>100</strong> شخص:</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي (احمرار البشرة و&rlm;الطفح الجلدي البارز والحكة)</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بضيق التنفس</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى (ارتفاع درجة الحرارة)</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأوجاع والآلام العامة</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الريح (الانتفاخ بسبب الغازات)</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الضعف</p><p dir="RTL">من بين الآثار الجانبية غير الشائعة التي قد تظهر في فحوصات الدم:</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد الخلايا المشاركة في تجلط الدم <em>(نقص الصفائح الدموية)</em>، أو في كل أنواع خلايا الدم<br /><em>(قلة الكريات الشاملة)</em></p><p dir="RTL"><strong>الآثار الجانبية النادرة</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span style='mso-element:field-begin'></span></b><span
dir=LTR></span><span dir=LTR></span><span dir=LTR><span dir=LTR></span><span
dir=LTR></span> DOCVARIABLE VAULT_ND_481f183c-7655-4edf-a27a-11ea7d567cb4 \*
MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span style='mso-element:field-end'></span></b><![endif]--></p><p dir="RTL">قد تصيب <strong>حتى شخص واحد من كل </strong><strong>1000</strong> شخص:</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات في الكبد، مثل تضخم الكبد أو الكبد الدهني</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحماض اللاكتيكي (راجع قسم <em>&quot;&rlm;الآثار الجانبية الأخرى المحتملة للعلاج المركب لفيروس نقص المناعة البشرية&quot;</em>)</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر؛ وهن عضلة القلب</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات (تشنجات)</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالاكتئاب والقلق وعدم القدرة على النوم (الأرق) وعدم القدرة على التركيز والشعور بالنعاس</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عسر الهضم وفقدان الشهية واضطراب في التذوق</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في لون الأظافر والجلد أو البشرة الداخلية في الفم</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور يشبه الأنفلونزا &mdash; الرعشة والتعرق والسعال</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالوخز في الجلد (كالإبر والدبابيس)</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كثرة التبول</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخم الثديين عند الرجال</p><p dir="RTL">من الآثار الجانبية النادرة التي قد تظهر في فحوصات الدم:</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم الحمراء <em>(عدم تنسج كريات الدم الحمراء النقية)</em></p><p dir="RTL"><strong>الآثار الجانبية شديدة الندرة</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span style='mso-element:field-begin'></span></b><span
dir=LTR></span><span dir=LTR></span><span dir=LTR><span dir=LTR></span><span
dir=LTR></span> DOCVARIABLE VAULT_ND_c0738eaa-4591-433b-a5df-88fe1f383766 \*
MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span style='mso-element:field-end'></span></b><![endif]--></p><p dir="RTL">قد تصيب <strong>حتى شخص واحد من كل </strong><strong>10000</strong> شخص:</p><p dir="RTL">من الآثار الجانبية شديدة الندرة التي قد تظهر في فحوصات الدم:</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل النخاع العظمي في إنتاج خلايا دم جديدة <em>(فقر الدم اللاتنسجي)</em></p><p dir="RTL"><strong>في حالة الإصابة بالآثار الجانبية</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span style='mso-element:field-begin'></span></b><span
dir=LTR></span><span dir=LTR></span><span dir=LTR><span dir=LTR></span><span
dir=LTR></span> DOCVARIABLE VAULT_ND_0aa5aa63-8a2d-4ed6-9865-090f0135f652 \*
MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span style='mso-element:field-end'></span></b><![endif]--></p><p dir="RTL">&ccedil;&nbsp; <strong>أخبر الطبيب أو الصيدلاني في حال تفاقم</strong> أي من الآثار الجانبية <strong>أو إذا أصبحت مزعجة</strong> أو إذا لاحظت آثارًا جانبية غير مبينة في هذه النشرة.</p><p dir="RTL"><strong>الآثار الجانبية الأخرى المحتملة للعلاج المركب لفيروس نقص المناعة البشرية</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span style='mso-element:field-begin'></span></b><span
dir=LTR></span><span dir=LTR></span><span dir=LTR><span dir=LTR></span><span
dir=LTR></span> DOCVARIABLE VAULT_ND_5e2c8df6-97b3-42ef-8230-31b0cf48cc9e \*
MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span style='mso-element:field-end'></span></b><![endif]--></p><p dir="RTL">قد تظهر بعض الحالات الأخرى أثناء علاج فيروس نقص المناعة البشرية.</p><p dir="RTL"><strong>احتمال نشاط العدوى السابقة</strong></p><p dir="RTL">يعاني المرضى المصابون بحالة متقدمة من عدوى فيروس نقص المناعة البشرية (الإيدز) من أجهزة مناعية ضعيفة ويصبحون أكثر عرضة للإصابة بعدوى خطيرة <em>(عدوى انتهازية)</em>. وعند بدء العلاج، ربما يلاحظ المرضى نشاط العدوى القديمة التي اختفت مسببةً ظهور علامات وأعراض الالتهاب. وعادة ما تنتج هذه الأعراض عن زيادة قوة جهاز المناعة بالجسم؛ حيث يبدأ الجسم في مكافحة هذه العدوى.</p><p dir="RTL">في حال ظهور أي من أعراض العدوى أثناء تناول ريتروڤير:</p><p dir="RTL">&ccedil;&nbsp; <strong>أخبر الطبيب في الحال</strong>. ولا تتناول أي أدوية أخرى لعلاج العدوى دون استشارة الطبيب.</p><p dir="RTL"><strong>قد يتغير شكل الجسم</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span style='mso-element:field-begin'></span></b><span
dir=LTR></span><span dir=LTR></span><span dir=LTR><span dir=LTR></span><span
dir=LTR></span> DOCVARIABLE VAULT_ND_61d697d5-23ab-457a-bedc-98895bb62095 \*
MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span style='mso-element:field-end'></span></b><![endif]--></p><p dir="RTL">قد يتسبب العلاج باستخدام ريتروڤير أو الأدوية الأخرى التي تحتوي على زيدوڤودين في فقد الدهون من الساقين والذراعين والوجه (ضمور شحمي). يجب أن يراقب طبيبك علامات الضمور الشحمي. قم بإبلاغ الطبيب عند ملاحظة فقد أي دهون من الساقين والذراعين والوجه. عندما تحدث هذه العلامات، سيقيم الطبيب ما إذا كان ينبغي التوقف عن استخدام ريتروڤير وتغيير علاج فيروس نقص المناعة البشرية. إذا توقفت عن تناول ريتروڤير، فقد يستغرق الأمر عدة أشهر لكي يتم استعادة الدهون المفقودة. قد لا يتم استعادة جميع الدهون المفقودة من الجسم.</p><p dir="RTL"><em>قد تظهر آثار أخرى في فحوصات الدم</em></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات السكر والأحماض الدهنية في الدم <em>(الدهون الثلاثية)</em> والكوليسترول في اختبارات الدم</p><p dir="RTL"><strong>يعتبر الحماض اللاكتيكي من الآثار الجانبية النادرة والخطيرة في الوقت نفسه</strong></p><p dir="RTL">يعاني بعض المرضى الذين يتناولون دواء ريتروڤير أو دواءً آخرًا مماثلاً له (كالأدوية النيوكليوزيدية المضادة لإنزيم المنتسخة المعاكس) من حالة مرضية تُعرف باسم الحماض اللاكتيكي علاوة على تضخم في الكبد. والحماض اللاكتيكي هو حالة طبية تحدث نتيجة تراكم حمض اللاكتيك في الجسم. وهي حالة نادرة، لكن إن حدثت، فهي تظهر عادةً بعد عدة أشهر من العلاج. ويمكن أن تمثل خطورة على حياة الإنسان وتسبب قصورًا في الأعضاء الداخلية.</p><p dir="RTL">ويشيع حدوث الحماض اللاكتيكي لدى النساء ومرضى الكبد.</p><p dir="RTL"><strong>من بين علامات الحماض اللاكتيكي:</strong><!--[if supportFields]><b style='mso-ansi-font-weight:
normal'><span style='font-style:normal;mso-ansi-font-style:italic'><span
style='mso-element:field-begin'></span></span></b><span dir=LTR></span><span
dir=LTR></span><span dir=LTR><span dir=LTR></span><span dir=LTR></span>
DOCVARIABLE VAULT_ND_38c25e17-f41c-4859-bbec-682bd6e11603 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span style='font-style:normal;mso-ansi-font-style:
italic'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>التنفس بعمق وصعوبة وسرعة في التنفس</strong></p><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>ضعف </strong>في الأطراف</p><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>فقدان الشهية وفقدان الوزن المفاجئ غير المبرر</strong></p><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الشعور بالتوعك </strong>(الغثيان)،<strong> الإعياء </strong>(القيء)</p><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>ألم المعدة</strong></p><p dir="RTL">خلال فترة العلاج سوف يراقب الطبيب ظهور أي علامات للحماض اللاكتيكي. إذا شعرت بأي من الأعراض المذكورة أعلاه أو أعراض أخرى تقلقك:</p><p dir="RTL"><strong>&ccedil;&nbsp; </strong><strong>توجه إلى الطبيب في أقرب وقت ممكن</strong>.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ ريتروڤير بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول ريتروڤير بعد تاريخ انتهاء الصلاحية المدون على العبوة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يخزن ريتروڤير في درجة حرارة أقل من 30&nbsp;درجة مئوية (86 درجة&nbsp;فهرنهايت).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ في مكان جاف بعيدًا عن الضوء</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة في هذا الدواء هي زيدوڤودين.<!--[if supportFields]><span
lang=AR-SA style='font-size:11.5pt;mso-bidi-font-family:Arial;text-transform:
none;font-weight:normal;mso-ansi-font-weight:bold'><span style='mso-element:
field-begin'></span> </span><span dir=LTR style='font-size:11.5pt;mso-bidi-font-family:
Arial;text-transform:none'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><span style='font-size:11.5pt;mso-bidi-font-family:Arial;
text-transform:none;font-weight:normal;mso-ansi-font-weight:bold'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='font-size:
11.5pt;mso-bidi-font-family:Arial;text-transform:none'>VAULT_ND_d181d647-93bd-4f5a-a5b6-7f15d166e1f4
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='font-size:11.5pt;mso-bidi-font-family:Arial;text-transform:none;
font-weight:normal;mso-ansi-font-weight:bold'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='font-size:11.5pt;mso-bidi-font-family:Arial;text-transform:
none;font-weight:normal;mso-ansi-font-weight:bold'><span style='mso-element:
field-end'></span></span><![endif]--></p><p>المكونات الأخرى هي:<!--[if supportFields]><span lang=AR-SA style='font-size:11.5pt;
mso-bidi-font-family:Arial;text-transform:none;font-weight:normal;mso-ansi-font-weight:
bold'><span style='mso-element:field-begin'></span> </span><span dir=LTR
style='font-size:11.5pt;mso-bidi-font-family:Arial;text-transform:none'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='font-size:11.5pt;mso-bidi-font-family:
Arial;text-transform:none;font-weight:normal;mso-ansi-font-weight:bold'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='font-size:
11.5pt;mso-bidi-font-family:Arial;text-transform:none'>VAULT_ND_6cce608b-a54c-4062-abdf-5e6e38edde91
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='font-size:11.5pt;mso-bidi-font-family:Arial;text-transform:none;
font-weight:normal;mso-ansi-font-weight:bold'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='font-size:11.5pt;mso-bidi-font-family:Arial;text-transform:
none;font-weight:normal;mso-ansi-font-weight:bold'><span style='mso-element:
field-end'></span></span><![endif]--></p><p>نشا وميكروكريستالين سليلوز وجليكولات نشا الصوديوم وستيرات الماغنيسيوم<!--[if supportFields]><span
lang=AR-SA style='font-size:11.5pt;mso-bidi-font-family:Arial;text-transform:
none;font-weight:normal;mso-ansi-font-weight:bold'><span style='mso-element:
field-begin'></span> </span><span dir=LTR style='font-size:11.5pt;mso-bidi-font-family:
Arial;text-transform:none'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><span style='font-size:11.5pt;mso-bidi-font-family:Arial;
text-transform:none;font-weight:normal;mso-ansi-font-weight:bold'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='font-size:
11.5pt;mso-bidi-font-family:Arial;text-transform:none'>VAULT_ND_630e055a-3b98-4d15-a611-8d24e831dca7
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='font-size:11.5pt;mso-bidi-font-family:Arial;text-transform:none;
font-weight:normal;mso-ansi-font-weight:bold'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='font-size:11.5pt;mso-bidi-font-family:Arial;text-transform:
none;font-weight:normal;mso-ansi-font-weight:bold'><span style='mso-element:
field-end'></span></span><![endif]--></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>شرائط فقاعية من كلوريد البولي فينيل/رقائق الألومنيوم<!--[if supportFields]><span
lang=AR-SA style='font-size:11.5pt;mso-bidi-font-family:Arial;text-transform:
none;font-weight:normal;mso-ansi-font-weight:bold'><span style='mso-element:
field-begin'></span> </span><span dir=LTR style='font-size:11.5pt;mso-bidi-font-family:
Arial;text-transform:none'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><span style='font-size:11.5pt;mso-bidi-font-family:Arial;
text-transform:none;font-weight:normal;mso-ansi-font-weight:bold'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='font-size:
11.5pt;mso-bidi-font-family:Arial;text-transform:none'>VAULT_ND_8b1186ed-17a0-4654-97b3-4dcb801835cd
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='font-size:11.5pt;mso-bidi-font-family:Arial;text-transform:none;
font-weight:normal;mso-ansi-font-weight:bold'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='font-size:11.5pt;mso-bidi-font-family:Arial;text-transform:
none;font-weight:normal;mso-ansi-font-weight:bold'><span style='mso-element:
field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا تتوفر جميع أحجام العبوات في السوق</p><p dir="RTL"><strong><em>ريتروڤير</em></strong> هو علامة تجارية مملوكة أو مرخصة لمجموعة شركات ڤيڤ هلثكير.</p><p dir="RTL">&copy;2023 مجموعة شركات ڤيڤ هلثكير، جميع الحقوق محفوظة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المصنعة:</strong></p><p dir="RTL">ديلفارم بوزنان أسبولكا أكسيجنا، أولي. جرانڤالسكا 189، 60- 322 بوزنان ، بولندا</p><p dir="RTL"><strong>مالك ترخيص التسويق:</strong></p><p dir="RTL">جلاكسو العربية السعودية المحدودة* جًدة، السعودية.</p><p dir="RTL">العنوان: صندوق بريد 22617 ، جدة 21416 ، المملكة العربية السعودية.</p><p dir="RTL"><em>*عضو في مجموعة شركات جلاكسو سميث كلاين.</em></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            رقم الإصدار: GDS40
تاريخ الإصدار: 27 مايو 2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 Retrovir 100 mg Capsules.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Capsules containing 100 mg zidovudine. 
–	100 mg gelatin capsules with opaque white cap and body, coded GSYJU.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard capsules.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>RETROVIR</em> is indicated in combination with other anti-retroviral agents for the treatment of Human Immunodeficiency Virus (HIV) infection in adults and children.</p><p><em>RETROVIR</em> is indicated for use in HIV-positive pregnant women and their newborn infants as it has been shown to reduce the rate of maternal-foetal transmission of HIV (<em>see Pregnancy and Lactation</em>)<em>.</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>RETROVIR</em> therapy should be initiated by a physician experienced in the management of HIV infection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Adults and adolescents weighing at least 30 kg</strong></p><p>The recommended dose of <em>RETROVIR</em> in combination with other anti-retroviral agents is 250 or 300 mg twice daily.</p><p>To ensure administration of the entire dose, the capsule(s) should ideally be swallowed without opening.&nbsp; For patients who are unable to swallow capsules, they may be opened, and the powder added to a small amount of semi-solid food or liquid, all of which should be consumed immediately.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Children </strong></p><p>To ensure administration of the entire dose, the capsule(s) should ideally be swallowed without opening.&nbsp; For patients who are unable to swallow capsules, they may be opened, and the powder added to a small amount of semi-solid food or liquid, all of which should be consumed immediately.</p><p><em>Children weighing at least 8 kg and less than 14 kg: </em></p><p>The recommended dose of <em>RETROVIR</em> is one 100 mg capsule twice daily.</p><p><em>Children weighing at least 14 kg and less than or equal to 21 kg: </em></p><p>The recommended dose of <em>RETROVIR</em> is one 100 mg capsule taken in the morning and two 100 mg capsules taken in the evening.</p><p><em>Children weighing more than 21 kg and less than 30 kg: </em></p><p>The recommended dose of <em>RETROVIR</em> is two 100 mg capsules twice daily.</p><p>Available data are insufficient to propose specific dosage recommendations for children weighing less than 4 kg (<em>see Prevention of maternal foetal transmission and Pharmacokinetics</em>).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Elderly</strong></p><p>Zidovudine pharmacokinetics have not been studied in patients over 65 years of age and no specific data are available. However, since special care is advised in this age group due to age-associated changes such as the decrease in renal function and alterations in haematological parameters, appropriate monitoring of patients before and during use of <em>RETROVIR</em> is advised.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Renal impairment</strong></p><p>In patients with severe renal impairment daily dosages of 300 to 400 mg should be appropriate. Haematological parameters and clinical response may influence the need for subsequent dosage adjustment. Haemodialysis and peritoneal dialysis have no significant effect on <em>RETROVIR</em> elimination whereas elimination of the glucuronide metabolite is increased. For patients with end-stage renal disease maintained on haemodialysis or peritoneal dialysis, the recommended dose is 100 mg every 6 to 8 h (<em>see&nbsp; Pharmacokinetics</em>).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Hepatic impairment</strong></p><p>Data in patients with cirrhosis suggest that accumulation of zidovudine may occur in patients with hepatic impairment because of decreased glucuronidation. Dosage adjustments may be necessary, but as there is only limited data available precise recommendations cannot be made. If monitoring of plasma zidovudine levels is not feasible, physicians will need to monitor for signs of intolerance and adjust the dose and/or increase the interval between doses as appropriate.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Patients with haematological adverse reactions</strong></p><p>Dosage reduction or interruption of <em>RETROVIR</em> therapy may be necessary in patients whose haemoglobin level falls to between 7.5 g/dl (4.65 mmol/l) and 9 g/dl (5.59 mmol/l) or whose neutrophil count falls to between 0.75 x 10<sup>9</sup>/l and 1.0 x 10<sup>9</sup>/l (<em>see&nbsp; Contraindications, Warnings and Precautions</em>).</p><ul><li><strong>Prevention of maternal-foetal transmission</strong></li></ul><p>The following <em>RETROVIR</em> dosage regimens have been shown to be effective (<em>see Pregnancy and Lactation</em>).</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>ACTG 076 study</em>: The recommended dose of <em>RETROVIR</em> for pregnant women (over 14 weeks of gestation) is 500 mg/day orally (100 mg five times daily) until the beginning of labour. During labour and delivery <em>RETROVIR</em> should be administered intravenously at 2 mg/kg bodyweight given over 1 h, followed by a continuous i.v. infusion at 1 mg/kg/h until the umbilical cord is clamped.</p><p>Neonates should be given <em>RETROVIR</em> 0.2&nbsp;mL/kg (2 mg/kg) bodyweight of oral solution every 6 h starting within 12 h after birth, and continuing until six weeks old.</p><p><strong>An appropriate sized syringe with 0.1 mL graduation should be used to ensure accurate dosing of neonates. </strong></p><p><strong>Table 1: Examples of Neonatal Dosing Recommendations for Retrovir Oral Solution for the Prevention of Mother to Child Transmission (PMTCT) of HIV in Neonates.</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:645px"><tbody><tr><td style="vertical-align:top"><p><strong>Neonate Body Weight in kilograms (kg)</strong></p></td><td style="vertical-align:top"><p><strong>Total volume of dose in millilitres (mL)</strong></p><p>0.2mL/kg</p></td><td style="vertical-align:top"><p><strong>How often should each dose be taken (in 24 hours)</strong></p></td><td style="vertical-align:top"><p><strong>Dose of zidovudine in milligrams (mg)</strong></p><p>2mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>2.0&nbsp;kg</p></td><td style="vertical-align:top"><p><strong>0.4&nbsp;mL </strong></p></td><td style="vertical-align:top"><p><strong>4 times </strong></p></td><td style="vertical-align:top"><p>4&nbsp;mg</p></td></tr><tr><td style="vertical-align:top"><p>5.0&nbsp;kg</p></td><td style="vertical-align:top"><p><strong>1.0&nbsp;mL </strong></p></td><td style="vertical-align:top"><p><strong>4 times</strong></p></td><td style="vertical-align:top"><p>10&nbsp;mg</p></td></tr></tbody></table><p>&nbsp;</p><p>Infants unable to receive oral dosing should be given <em>RETROVIR</em> infusion intravenously at 1.5 mg/kg bodyweight infused over 30 min every 6 h.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Thailand-Centers for Disease Control (CDC) study</em>: The recommended dose of <em>RETROVIR</em> for pregnant women from week 36 of gestation is 300 mg <em>RETROVIR</em> twice daily orally until onset of labour, and 300 mg <em>RETROVIR</em> orally every 3 h from onset of labour until delivery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                RETROVIR is contraindicated in patients known to be hypersensitive to zidovudine, or to any of the components of the formulations.
RETROVIR should not be given to patients with abnormally low neutrophil counts (less than 0.75 x 109/l) or abnormally low haemoglobin levels (less than 7.5 g/dl or 4.65 mmol/l) (see Warnings and Precautions).
Retrovir is contra-indicated in new born infants with hyperbilirubinaemia requiring
treatment other than phototherapy, or with increased transaminase levels of over five times the upper limit of normal.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients should be cautioned about the concomitant use of self-administered medications (<em>see Interactions</em>).</p><p><em>RETROVIR</em> is not a cure for HIV infection and patients remain at risk of developing illnesses which are associated with immune suppression, including opportunistic infections and neoplasms. Whilst it has been shown to reduce the risks of opportunistic infections, data on the development of neoplasms, including lymphomas, are limited. The available data on patients treated for advanced HIV disease indicate that the risk of lymphoma development is consistent with that observed in untreated patients. In patients with early HIV disease on long-term treatment the risk of lymphoma development is unknown.</p><p>Pregnant women considering the use of <em>RETROVIR</em> during pregnancy for prevention of HIV transmission to their infants should be advised that transmission may still occur in some cases despite therapy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Haematological adverse reactions</em></strong></p><p>Anaemia (usually not observed before six weeks of <em>RETROVIR</em> therapy but occasionally occurring earlier), neutropenia (usually not observed before four weeks&#39; therapy but sometimes occurring earlier) and leucopenia (usually secondary to neutropenia) can be expected to occur in patients with advanced symptomatic HIV disease receiving <em>RETROVIR</em>. These occurred more frequently at higher dosages (1200 to 1500 mg/day) and in patients with poor bone marrow reserve prior to treatment, particularly with advanced HIV disease.</p><p>Haematological parameters should be carefully monitored. For patients with advanced symptomatic HIV disease it is generally recommended that blood tests are performed at least every two weeks for the first three months of therapy and at least monthly thereafter. In patients with early HIV disease (where bone marrow reserve is generally good), haematological adverse reactions are infrequent. Depending on the overall condition of the patient, blood tests may be performed less often, for example every one to three months.</p><p>If the haemoglobin level falls to between 7.5 g/dl (4.65 mmol/l) and 9 g/dl (5.59 mmol/l) or the neutrophil count falls to between 0.75 x 10<sup>9</sup>/l and 1.0 x 10<sup>9</sup>/l, the daily dosage may be reduced until there is evidence of marrow recovery; alternatively, recovery may be enhanced by brief (2 to 4 weeks) interruption of <em>RETROVIR</em> therapy. Marrow recovery is usually observed within 2 weeks after which time <em>RETROVIR</em> therapy at a reduced dosage may be reinstituted. In patients with significant anaemia, dosage adjustments do not necessarily eliminate the need for transfusions (<em>see Contraindications</em>).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Lactic acidosis/severe hepatomegaly with steatosis</em></strong><em> </em></p><p>Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of antiretroviral nucleoside analogues either alone or in combination, including zidovudine. A majority of these cases have been in women.</p><p>Clinical features which may be indicative of the development of lactic acidosis include generalised weakness, anorexia and sudden unexplained weight loss, gastrointestinal symptoms and respiratory symptoms (dyspnoea and tachypnoea).</p><p>Caution should be exercised when administering <em>RETROVIR,</em> particularly to those with known risk factors for liver disease. Treatment with <em>RETROVIR</em> should be suspended in any patient who develops clinical or laboratory findings suggestive of lactic acidosis with or without hepatitis (which may include hepatomegaly and steatosis even in the absence of marked transaminase elevations).</p><p><strong>Lactic acidosis</strong> has a high mortality and may be associated with pancreatitis, liver failure, or renal failure.</p><p>Lactic acidosis generally occurred after a few or several months of treatment.</p><p>Treatment with zidovudine should be discontinued in the setting of symptomatic</p><p>hyperlactatemia and metabolic/lactic acidosis, progressive hepatomegaly, or rapidly</p><p>elevating aminotransferase levels.</p><p>Caution should be exercised when administering zidovudine to any patient (particularly obese women) with hepatomegaly, hepatitis or other known risk factors for liver disease and hepatic steatosis (including certain medicinal products and alcohol). Patients coinfected with hepatitis C and treated with alpha interferon and ribavirin may constitute a special risk.</p><p>Patients at increased risk should be followed closely.</p><p>Mitochondrial dysfunction following exposure in utero: Nucleoside and nucleotide analogues may impact mitochondrial function to a variable degree, which is most pronounced with stavudine, didanosine and zidovudine. There have been reports of mitochondrial dysfunction in HIV-negative infants exposed in utero and/or post-natally to nucleoside analogues; these have predominantly concerned treatment with regimens containing zidovudine. The main adverse reactions reported are haematological disorders (anaemia, neutropenia) and metabolic disorders (hyperlactatemia, hyperlipasaemia). These events have often been transitory. Late-onset neurological disorders have been reported rarely (hypertonia, convulsion, abnormal behaviour). Whether such neurological disorders are transient or permanent is currently unknown. These findings should be considered for any child exposed in utero to nucleoside and nucleotide analogues, who presents with severe clinical findings of unknown etiology, particularly neurologic findings. These findings do not affect current recommendations to use antiretroviral therapy in pregnant women to prevent vertical transmission of HIV.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Lipoatrophy </em></strong></p><p>Treatment with zidovudine has been associated with loss of subcutaneous fat. The incidence and severity of lipoatrophy are related to cumulative exposure.&nbsp; This fat loss, which is most evident in the face, limbs and buttocks, may be only partially reversible and improvement may take several months when switching to a zidovudine-free regimen. Patients should be regularly assessed for signs of lipoatrophy during therapy with <em>RETROVIR</em> and other zidovudine containing products (Combivir and Trizivir), and if feasible therapy should be switched to an alternative regimen if there is suspicion of lipoatrophy development.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Serum lipids and blood glucose </em></strong></p><p>Serum lipid and blood glucose levels may increase during antiretroviral therapy. Disease control and life style changes may also be contributing factors. Consideration should be given to the measurement of serum lipids and blood glucose. Lipid disorders should be managed as clinically appropriate.</p><p><em><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Immune Reconstitution Syndrome (IRIS)</strong></em></p><p>In HIV-infected patients with severe immune deficiency at the time of initiation of anti-retroviral therapy (ART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise and cause serious clinical conditions, or aggravation of symptoms. Typically, such reactions have been observed within the first few weeks or months of initiation of ART.&nbsp; Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections and Pneumocystis jiroveci (P. carinii) pneumonia. Any inflammatory symptoms must be evaluated without delay and treatment initiated when necessary. Autoimmune disorders (such as Graves&rsquo; disease, polymyositis and Guillain-Barre syndrome) have also been reported to occur in the setting of immune reconstitution, however, the time to onset is more variable, and can occur many months after initiation of treatment and sometimes can be an atypical presentation.&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Patients co-infected with hepatitis C virus</em></strong></p><p>Exacerbation of anaemia due to ribavirin has been reported when zidovudine is part of the regimen used to treat HIV although the exact mechanism remains to be elucidated. Therefore, the co-administration of ribavirin and zidovudine is not advised and consideration should be given to replacing zidovudine in a combination ART regimen if this is already established. This is particularly important in patients with a known history of zidovudine induced anaemia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zidovudine is primarily eliminated by hepatic conjugation to an inactive glucuronidated metabolite. Active substances which are primarily eliminated by hepatic metabolism especially via glucuronidation may have the potential to inhibit metabolism of zidovudine. The interactions listed below should not be considered exhaustive but are representative of the classes of medicinal products where caution should be exercised.</p><p><strong><em>Atovaquone:</em></strong> zidovudine does not appear to affect the pharmacokinetics of atovaquone.&nbsp; However, pharmacokinetic data have shown that atovaquone appears to decrease the rate of metabolism of zidovudine to its glucuronide metabolite (steady state AUC of zidovudine was increased by 33% and peak plasma concentration of the glucuronide was decreased by 19%).&nbsp; At zidovudine dosages of 500 or 600 mg/day it would seem unlikely that a three-week, concomitant course of atovaquone for the treatment of acute PCP would result in an increased incidence of adverse reactions attributable to higher plasma concentrations of zidovudine.&nbsp; Extra care should be taken in monitoring patients receiving prolonged atovaquone therapy.</p><p><strong><em>Clarithromycin:</em></strong> clarithromycin tablets reduce the absorption of zidovudine.&nbsp; This can be avoided by separating the administration of zidovudine and clarithromycin by at least two hours.</p><p><strong><em>Lamivudine</em></strong><em>:</em> a modest increase in C<sub>max</sub> (28%) was observed for zidovudine when administered with lamivudine, however overall exposure (AUC) was not significantly altered. Zidovudine has no effect on the pharmacokinetics of lamivudine.</p><p><strong><em>Phenytoin</em></strong><em>:</em> phenytoin blood levels have been reported to be low in some patients receiving <em>RETROVIR</em>, while in one patient a high level was noted. These observations suggest that phenytoin levels should be carefully monitored in patients receiving both medicinal products.</p><p><strong><em>Probenecid</em></strong><em>:</em> limited data suggest that probenecid increases the mean half-life and AUC of zidovudine by decreasing glucuronidation. Renal excretion of the glucuronide (and possibly zidovudine itself) is reduced in the presence of probenecid.</p><p><strong><em>Rifampicin</em></strong><em>:</em> limited data suggests that co-administration of zidovudine and rifampicin decreases AUC of zidovudine by 48% &plusmn; 34%. However the clinical significance of this is unknown.</p><p><strong><em>Stavudine</em></strong><em>:</em> zidovudine may inhibit the intracellular phosphorylation of stavudine when the two medicinal products are used concurrently.&nbsp; Stavudine is therefore not recommended to be used in combination with <em>RETROVIR</em>.</p><p><strong><em>Miscellaneous</em></strong><em>:</em> other active substances including but not limited to aspirin, codeine, morphine, methadone, indomethacin, ketoprofen, naproxen, oxazepam, lorazepam, cimetidine, clofibrate, dapsone and isoprinosine may alter the metabolism of zidovudine by competitively inhibiting glucuronidation or directly inhibiting hepatic microsomal metabolism. Careful thought should be given to the possibilities of interactions before using such medicinal products, particularly for chronic therapy, in combination with <em>RETROVIR</em>.</p><p>Concomitant treatment, especially acute therapy, with potentially nephrotoxic or myelosuppressive medicinal products (for example systemic pentamidine, dapsone, pyrimethamine, co-trimoxazole, amphotericin, flucytosine, ganciclovir, interferon, vincristine, vinblastine and doxorubicin) may also increase the risk of adverse reactions to <em>RETROVIR</em>. If concomitant therapy with any of these medicinal products is necessary then extra care should be taken in monitoring renal function and haematological parameters and, if required, the dosage of one or more agents should be reduced.</p><p>Since some patients receiving <em>RETROVIR</em> may continue to experience opportunistic infections, concomitant use of prophylactic antimicrobial therapy may have to be considered. Such prophylaxis has included co-trimoxazole, aerosolised pentamidine, pyrimethamine and aciclovir. Limited data from clinical trials of oral RETROVIR do not indicate a significantly increased risk of adverse reactions to <em>RETROVIR</em> with these medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Fertility</strong></p><p>There are no data on the effect of <em>RETROVIR</em> on human female fertility. In men, zidovudine<em> </em>has been shown to have no effect on sperm count, morphology or motility.</p><p><strong>Pregnancy</strong></p><p>Zidovudine has been evaluated in the Antiretroviral Pregnancy Registry (APR) in over 13,000 women during pregnancy and postpartum. Available human data from the APR do not show an increased risk of major birth defects for zidovudine compared to the background rate <em>(see Clinical Studies).</em></p><p>The safe use of zidovudine in human pregnancy has not been established in adequate and well-controlled trials investigating congenital abnormalities. Therefore administration of <em>RETROVIR</em> in pregnancy should be considered only if the expected benefit outweighs the possible risk to the foetus.</p><p>Zidovudine has been shown to cross the placenta in humans (<em>see Pharmacokinetics</em>). Zidovudine has been associated with findings in animal reproductive studies (<em>see</em> <em>Pre-Clinical Safety Data</em>). Pregnant women considering using <em>RETROVIR</em> during pregnancy should be made aware of these findings.</p><p>There have been reports of mild, transient elevations in serum lactate levels, which may be due to mitochondrial dysfunction, in neonates and infants exposed in utero or peri-partum to nucleoside reverse transcriptase inhibitors (NRTIs). The clinical relevance of transient elevations in serum lactate is unknown. There have also been very rare reports of developmental delay, seizures and other neurological disease. However, a causal relationship between these events and NRTI exposure in utero or peri-partum has not been established. These findings do not affect current recommendations to use antiretroviral therapy in pregnant women to prevent vertical transmission of HIV.</p><p><strong>Maternal-foetal transmission</strong></p><p>In study ACTG 076 the use of <em>RETROVIR</em> in pregnant women over 14 weeks of gestation, with subsequent treatment of their newborn infants, has been shown to significantly reduce the rate of maternal-foetal transmission of HIV (23% infection rate for placebo versus 8% for <em>RETROVIR</em>). Oral <em>RETROVIR</em> therapy began between weeks 14 and 34 of gestation and continued until onset of labour. During labour and delivery <em>RETROVIR</em> was administered intravenously. The newborn infants received <em>RETROVIR</em> orally until 6 weeks old. Infants unable to receive oral dosing were given the i.v. formulation.</p><p>In the 1998 Thailand CDC study, use of oral <em>RETROVIR</em> therapy only, from week 36 of gestation until delivery, significantly reduced the rate of maternal-foetal transmission of HIV (19% infection rate for placebo versus 9% for <em>RETROVIR</em>). No mothers in this study breast fed their infants.</p><p>It is unknown whether there are any long-term consequences of <em>in utero</em> and infant exposure to zidovudine. Based on the animal carcinogenicity/mutagenicity findings a carcinogenic risk to humans cannot be excluded (<em>see Preclinical Safety Data</em>). The relevance of these findings to both infected and uninfected infants exposed to zidovudine is unknown. However, pregnant women considering using <em>RETROVIR</em> during pregnancy should be made aware of these findings.</p><p><strong>Lactation</strong></p><p>Health experts recommend that where possible women infected with HIV do not breast feed their infants in order to avoid the transmission of HIV. In settings where formula feeding is not feasible, local official lactation and treatment guidelines should be followed when considering breast feeding during antiretroviral therapy.</p><p>After administration of a single dose of 200 mg <em>RETROVIR</em> to HIV-infected women, the mean concentration of zidovudine was similar in human milk and serum. In other studies following repeat oral dose of 300&nbsp;mg zidovudine twice daily (given either as a single entity or as <em>COMBIVIR</em> or <em>TRIZIVIR</em>) the maternal plasma:breast milk ratio ranged between 0.4 and 3.2.&nbsp; Zidovudine median infant serum concentration was 24&nbsp;ng/mL in one study and was below assay limit of quantification (30&nbsp;ng/mL) in another study. Intracellular zidovudine triphosphate (active metabolite of zidovudine) levels in breastfed infants were not measured therefore the clinical relevance of the serum concentrations of the parent compound measured is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There have been no studies to investigate the effect of <em>RETROVIR</em> on driving performance or the ability to operate machinery. Further, a detrimental effect on such activities cannot be predicted from the pharmacology of the active substance. Nevertheless, the clinical status of the patient and the adverse event profile of <em>RETROVIR</em> should be borne in mind when considering the patient&#39;s ability to drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The adverse event profile appears similar for adults and children.&nbsp; The following events have been reported in patients treated with <em>RETROVIR</em>.</p><p>The following convention has been utilised for the classification of undesirable effects:</p><p>very common (&gt;1/10), common (&gt;1/100, &lt;1/10), uncommon (&gt;1/1,000, &lt;1/100), rare (&gt;1/10,000, &lt;1/1,000), very rare (&lt;1/10,000).</p><p>&nbsp;</p><p><strong><em>Blood and lymphatic system disorders</em></strong></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaemia (which may require transfusions), neutropenia and leucopenia.</p><p>These occur more frequently at higher dosages (1200-1500mg/day) and in patients with advanced HIV disease (especially when there is poor bone marrow reserve prior to treatment), and particularly in patients with CD4 cell counts less than 100/mm<sup>3</sup>. Dosage reduction or cessation of therapy may become necessary (<em>see Warnings and Precautions</em>). The incidence of neutropenia was also increased in those patients whose neutrophil counts, haemoglobin levels and serum vitamin B<sub>12</sub> levels were low at the start of <em>RETROVIR</em> therapy.</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; Thrombocytopenia and pancytopenia (with marrow hypoplasia).</p><p>Rare: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pure red cell aplasia.</p><p>Very rare: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Aplastic anaemia.</p><p><strong><em>Metabolism and nutrition disorders </em></strong></p><p>Common: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hyperlactataemia.</p><p>Rare: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lactic acidosis (<em>see Warnings and Precautions</em>), anorexia.</p><p>Treatment with zidovudine has been associated with loss of subcutaneous fat <em>(see Warnings and Precautions).</em></p><p><strong><em>Psychiatric disorders</em></strong></p><p>Rare: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anxiety and depression.</p><p><strong><em>Nervous system disorders</em></strong></p><p>Very common: &nbsp;&nbsp;&nbsp;&nbsp; Headache.</p><p>Common: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness.</p><p>Rare: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Insomnia, paraesthesia, somnolence, loss of mental acuity, convulsions.</p><p><strong><em>Cardiac disorders</em> </strong></p><p>Rare: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cardiomyopathy.</p><p><strong><em>Respiratory, thoracic and mediastinal disorders</em></strong></p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dyspnoea.</p><p>Rare: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cough.</p><p><strong><em>Gastrointestinal disorders</em></strong></p><p>Very common: &nbsp;&nbsp;&nbsp;&nbsp; Nausea.</p><p>Common: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting, abdominal pain, and diarrhoea.</p><p>Uncommon: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flatulence.</p><p>Rare: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oral mucosa pigmentation, taste disturbance and dyspepsia.&nbsp; Pancreatitis.</p><p><strong><em>Hepatobilary disorders</em></strong></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Raised blood levels of liver enzymes and bilirubin.</p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liver disorders such as severe hepatomegaly with steatosis.</p><p><strong><em>Skin and subcutaneous tissue disorders</em></strong></p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; Rash and pruritus.</p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nail and skin pigmentation, urticaria and sweating.</p><p><strong><em>Musculoskeletal and connective tissue disorders</em></strong></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; Myalgia.</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; Myopathy.</p><p><strong><em>Renal and urinary disorders</em></strong></p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; Urinary frequency.</p><p><strong><em>Reproductive system and breast disorders</em></strong></p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gynaecomastia.</p><p><strong><em>General disorders and administration site conditions </em></strong></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Malaise.</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; Fever, generalised pain and asthenia.</p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; Chills, chest pain and influenza-like syndrome.</p><p>The available data from both placebo-controlled and open-labelled studies indicate that the incidence of nausea and other frequently reported clinical adverse events consistently decreases over time during the first few weeks of therapy with <em>RETROVIR</em>.</p><p><strong><em>Adverse reactions with RETROVIR for the prevention of maternal-foetal transmission</em></strong></p><p>In a placebo-controlled trial (ACTG 076), <em>RETROVIR</em> was well tolerated in pregnant women at the doses recommended for this indication. Clinical adverse events and laboratory test abnormalities were similar in the <em>RETROVIR</em> and placebo groups.</p><p>In the same trial, haemoglobin concentrations in infants exposed to <em>RETROVIR</em> for this indication were marginally lower than in infants in the placebo group, but transfusion was not required. Anaemia resolved within 6 weeks after completion of <em>RETROVIR</em> therapy. Other clinical adverse events and laboratory test abnormalities were similar in the <em>RETROVIR</em> and placebo groups. The long-term consequences of <em>in utero</em> and infant exposure to <em>RETROVIR</em> are unknown.</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p><strong><em>Kingdom of Saudi Arabia</em></strong></p><p><strong>-National Pharmacovigilance centre (NPC)</strong></p><ul><li>Fax: +966-11-205-7662</li><li>SFDA Call Center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p><p><strong>-GlaxoSmithKline - Head Office, Jeddah</strong></p><ul><li>Tel:&nbsp; +966-12-6536666</li><li>Mobile: +966-56-904-9882</li><li>Email: saudi.safety@gsk.com</li><li>website: https://gskpro.com/en-sa/</li><li>P.O. Box 55850, Jeddah 21544, Saudi Arabia</li></ul><p><strong>For any information about this medicinal product, please contact:</strong></p><p><strong>GlaxoSmithKline - Head Office, Jeddah</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: gcc.medinfo@gsk.com<u> </u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://gskpro.com/en-sa/<u>&nbsp; </u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Symptoms and Signs</strong></p><p>No specific symptoms or signs have been identified following acute overdose with <em>RETROVIR</em>, apart from those listed as undesirable effects.</p><p><strong>Treatment</strong></p><p>Patients should be observed closely for evidence of toxicity (<em>see Adverse Reactions</em>) and given the necessary supportive therapy.</p><p>Haemodialysis and peritoneal dialysis appear to have a limited effect on elimination of zidovudine but enhance the elimination of the glucuronide metabolite.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group - nucleoside analogue - ATC Code J05A F01.</p><p>Zidovudine is an antiviral agent which is highly active <em>in vitro</em> against retroviruses including HIV.</p><p>Zidovudine is phosphorylated in both infected and uninfected cells to the monophosphate (MP) derivative by cellular thymidine kinase. Subsequent phosphorylation of zidovudine‑MP to the diphosphate (DP), and then the triphosphate (TP) derivative is catalysed by cellular thymidylate kinase and non-specific kinases respectively. Zidovudine-TP acts as an inhibitor of and substrate for the viral reverse transcriptase. The formation of further proviral DNA is blocked by incorporation of zidovudine-TP into the chain and subsequent chain termination.&nbsp; Competition by zidovudine-TP for HIV reverse transcriptase is approximately 100-fold greater than for cellular DNA polymerase alpha. No antagonistic effects in vitro were seen with zidovudine and other antiretrovirals (tested agents: abacavir, didanosine, lamivudine and interferon-alpha).</p><p>Resistance to thymidine analogues (of which zidovudine is one) is well characterised and is conferred by the stepwise accumulation of up to six specific mutations in the HIV reverse transcriptase at codons 41, 67, 70, 210, 215 and 219. Viruses acquire phenotypic resistance to thymidine analogues through the combination of mutations at codons 41 and 215 or by the accumulation of at least four of the six mutations. These thymidine analogue mutations alone do not cause high-level cross-resistance to any of the other nucleosides, allowing for the subsequent use of any of the other approved reverse transcriptase inhibitors.</p><p>Two patterns of multi-drug resistance mutations, the first characterised by mutations in the HIV reverse transcriptase at codons 62, 75, 77, 116 and 151 and the second typically involving a T69S mutation plus a 6-base pair insert at the same position, result in phenotypic resistance to zidovudine as well as to the other approved nucleoside reverse transcriptase inhibitors. Either of these two patterns of multinucleoside resistance mutations severely limits future therapeutic options.</p><p>Reduced <em>in vitro</em> sensitivity to zidovudine has been reported for HIV isolates from patients who have received prolonged courses of <em>RETROVIR</em> therapy. The available information indicates that for early HIV disease, the frequency and degree of reduction of <em>in vitro</em> sensitivity is notably less than for advanced disease.</p><p>The relationships between <em>in vitro</em> susceptibility of HIV to zidovudine and clinical response to therapy remain under investigation. <em>In vitro</em>&nbsp; susceptibility testing has not been standardised and results may therefore vary according to methodological factors.</p><p>Studies <em>in vitro </em>of zidovudine in combination with lamivudine<em> </em>indicate that zidovudine‑resistant virus isolates can become zidovudine sensitive when they simultaneously acquire resistance to lamivudine. Evidence from clinical studies show that lamivudine plus zidovudine delays the emergence of zidovudine-resistant isolates in individuals with no prior anti- retroviral&nbsp; therapy. .</p><p>Zidovudine has been widely used as a component of antiretroviral combination therapy with other antiretroviral agents of the same class (nucleoside reverse transcriptase inhibitors) or different classes (protease inhibitors, non-nucleoside reverse transcriptase inhibitors).</p><p><strong><em>Post-exposure prophylaxis (PEP):</em></strong></p><p>Internationally recognised guidelines (Centre for Disease Control and Prevention - June 1998), recommend that in the event of accidental exposure to HIV infected blood e.g. from a needlestick injury, a combination of <em>RETROVIR</em> and <em>EPIVIR</em>&trade;&nbsp; should be administered promptly (within 1 to 2 h).&nbsp; In cases of higher risk of infection a protease inhibitor should be included in the regimen. It is recommended that antiretroviral prophylaxis be continued for four weeks. No controlled clinical studies have been carried out in post-exposure prophylaxis and supporting data is limited.&nbsp; Seroconversion may still occur despite prompt treatment with antiretroviral agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption</strong></p><p>Zidovudine is well absorbed from the gut and, at all dose levels studied, the bioavailability was 60 to 70%. From a Phase I study, mean steady state peak (C[ss]max) and trough (C[ss]min) plasma concentrations following oral administration of zidovudine (in solution) at doses of 5 mg/kg every 4 h were 7.1 and 0.4 micromol (or 1.9 and 0.1 micrograms/ml) respectively. From a bioequivalence study, mean C[ss]max and C[ss] min levels following oral administration of zidovudine capsules every 4 h and dose normalised to 200 mg were 4.5 micromol (or 1.2 micrograms/ml) and 0.4 micromol (or 0.1 micrograms/ml) respectively.</p><p>&nbsp;</p><p><strong>Bioequivalence</strong></p><p>In HIV-infected patients on zidovudine therapy, the 300 mg zidovudine tablet at steady state was bioequivalent to the 250 mg capsule, when adjusted for dose. As the kinetics of zidovudine are dose-independent following multiple dose oral administration, the 200 mg <em>RETROVIR</em> tablets of identical formulation to the 300 mg tablet can also be considered bioequivalent to the 250 mg capsule after adjustment for dose.</p><p><em>RETROVIR</em> oral solution was shown, in patients, to be bioequivalent to <em>RETROVIR</em> capsules in respect to the area under the zidovudine plasma concentration-time curve (AUC). The absorption of <em>RETROVIR</em> following the administration of the oral solution was marginally faster than that following the administration of capsules, with mean times to peak concentrations of 0.5 and 0.8 h respectively. Mean values for C[ss]max, dose- normalised to 200 mg were 5.8 micromol (or 1.55 micrograms/ml) and 4.5 micromol (1.2 micrograms/ml) for oral solution and capsules respectively. These data were generated using the US oral <em>RETROVIR</em> syrup but can be considered to apply equally to <em>RETROVIR</em> oral solution.</p><p>&nbsp;</p><p><strong><em>Solution for infusion:</em></strong></p><p>Dose-independent kinetics were observed in patients receiving 1 h infusions of 1 to 5&nbsp;mg/kg three to six times daily. Mean steady state peak (C<sub>ss</sub>max) and trough (C<sub>ss</sub>min) plasma concentrations in adults following a 1 h infusion of 2.5&nbsp;mg/kg every 4 h were 4.0 and 0.4 micromol respectively (or 1.1 and 0.1 micrograms/ml).</p><p>Distribution</p><p>From studies with i.v.zidovudine, the mean terminal plasma half- life was 1.1 h, the mean total body clearance was 27.1 ml/min/kg and the apparent volume of distribution was 1.6 l/kg.</p><p>In adults, the average cerebrospinal fluid/plasma zidovudine concentration ratio 2 to 4 h after dosing was found to be approximately 0.5. Data indicate that zidovudine crosses the placenta and is found in amniotic fluid and foetal blood. Zidovudine has also been detected in semen and milk.</p><p>Plasma protein binding is relatively low (34 to 38%) and interactions with other active substances involving binding site displacement are not anticipated.</p><p>Metabolism</p><p>The 5&#39;-glucuronide of zidovudine is the major metabolite in both plasma and urine, accounting for approximately 50 to 80% of the administered dose eliminated by renal excretion. 3&#39;amino- 3&#39;- deoxythymidine (AMT) has been identified as a metabolite of zidovudine following i.v. dosing.</p><p>Elimination</p><p>Renal clearance of zidovudine greatly exceeds creatinine clearance, indicating that significant tubular secretion takes place.</p><p>Special Patient Populations</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Children</strong></p><p>In children over the age of 5 to 6 months, the pharmacokinetic profile of zidovudine is similar to that in adults.</p><p>Zidovudine is well absorbed from the gut and, at all dose levels studied, its bioavailability was 60 to 74% with a mean of 65%. C[ss]max levels were 4.45 micromol (1.19 micrograms/ml) following a dose of 120 mg zidovudine (in solution)/m<sup>2</sup> body surface area and 7.7 micromol (2.06 micrograms/ml) at 180 mg/m<sup>2</sup> body surface area.</p><p>In children, the mean cerebrospinal fluid/plasma zidovudine concentration ratio ranged from 0.52 to 0.85, as determined during oral therapy 0.5 to 4 h after dosing and was 0.87 as determined during i.v. therapy 1 to 5 h after a 1 h infusion. During continuous i.v. infusion, the mean steady-state cerebrospinal fluid/plasma concentration ratio was 0.24.</p><p>With i.v. dosing, the mean terminal plasma half-life and total body clearance were 1.5 h and 30.9 ml/min/kg respectively. The major metabolite is the 5&#39;-glucuronide. After i.v. dosing, 29% of the dose was recovered unchanged in the urine and 45% excreted as the glucuronide. Renal clearance of zidovudine greatly exceeds creatinine clearance indicating that significant tubular secretion takes place.</p><p>The data available on the pharmacokinetics in neonates and young infants indicate that glucuronidation of zidovudine is reduced with a consequent increase in bioavailability, reduction in clearance and longer half-life in infants less than 14 days old but thereafter the pharmacokinetics appear similar to those reported in adults.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Elderly</strong></p><p>The pharmacokinetics of zidovudine have not been studied in patients over 65 years of age.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Renal Impairment</strong></p><p>Compared to healthy subjects, patients with advanced renal failure have a 50% higher peak plasma concentration of zidovudine. Systemic exposure (measured as area under the zidovudine concentration-time curve) is increased 100%; the half- life is not significantly altered. In renal failure there is substantial accumulation of the major, glucuronide metabolite but this does not appear to cause toxicity. Haemodialysis and peritoneal dialysis have no significant effect on zidovudine elimination whereas elimination of the glucuronide metabolite is increased (<em>see Dosage and Administration</em>).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Hepatic Impairment</strong></p><p>Data in patients with cirrhosis suggest that accumulation of zidovudine may occur in patients with hepatic impairment because of decreased glucuronidation. Dosage adjustments may be necessary, but as there is only limited data available precise recommendations cannot be made (<em>see Dosage and Administration</em>).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Pregnancy</strong></p><p>The pharmacokinetics of zidovudine has been investigated in a study of eight women during the last trimester of pregnancy. As pregnancy progressed, there was no evidence of accumulation of zidovudine. The pharmacokinetics of zidovudine was similar to that of non-pregnant adults. Consistent with passive transmission of zidovudine across the placenta, zidovudine concentrations in infant plasma at birth were essentially equal to those in maternal plasma at delivery.</p><p><strong>Clinical Studies</strong></p><p>The Antiretroviral Pregnancy Registry (APR) has received reports of over 13,000 exposures to zidovudine during pregnancy resulting in live birth. These consist of over 4,100 exposures during the first trimester, over 9,300 exposures during the second/third trimester and included 133 and 264 birth defects respectively. The prevalence (95% CI) of defects in the first trimester was 3.2% (2.7, 3.8%) and in the second/third trimester, 2.8% (2.5, 3.2%). This proportion is not significantly higher than those reported in the two population-based surveillance systems (2.72 per 100 live births and 4.17 per 100 live births respectively). The APR does not show an increased risk of major birth defects zidovudine compared to the background rate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><!--[if !supportLists]--></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Mutagenicity</strong></p><p>No evidence of mutagenicity was observed in the Ames test. However, zidovudine was weakly mutagenic in a mouse lymphoma cell assay and was positive in an <em>in vitro</em> cell transformation assay. Clastogenic effects were observed in an <em>in vitro</em> study in human lymphocytes and <em>in vivo</em> oral repeat dose micronucleus studies in rats and mice. An <em>in vivo</em> cytogenetic study in rats did not show chromosomal damage. A study of the peripheral blood lymphocytes of eleven AIDS patients showed a higher chromosome breakage frequency in those who had received <em>RETROVIR</em> than in those who had not.&nbsp; A pilot study has demonstrated that zidovudine is incorporated into leukocyte nuclear DNA of adults, including pregnant women, taking <em>RETROVIR</em> as treatment for HIV-1 infection, or for the prevention of mother to child viral transmission. Zidovudine was also incorporated into DNA from cord blood leukocytes of infants from zidovudine-treated mothers. &nbsp;The clinical significance of these findings is unknown.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Carcinogenecity</strong></p><p>In oral carcinogenicity studies with zidovudine in mice and rats, late appearing vaginal epithelial tumours were observed. There were no other zidovudine-related tumours observed in either sex of either species. A subsequent intravaginal carcinogenicity study confirmed the hypothesis that the vaginal tumours were the result of long term local exposure of the rodent vaginal epithelium to high concentrations of unmetabolised zidovudine in urine. The predictive value of rodent carcinogenicity studies for humans is uncertain and thus the clinical significance of these findings is unclear.</p><p>In addition two transplacental carcinogenicity studies have been conducted in mice. One study, by the US National Cancer Institute, administered zidovudine at maximum tolerated doses to pregnant mice from day 12 to 18 of gestation. One year post-natally, there was an increase in the incidence of tumours in the lung, liver and female reproductive tract of offspring exposed to the highest dose level (420mg/kg/term body weight).</p><p>In a second study, mice were administered zidovudine at doses up to 40 mg/kg for 24 months, with exposure beginning prenatally on gestation day 10. Treatment related findings were limited to late-occurring vaginal epithelial tumours, which were seen with a similar incidence and time of onset as in the standard oral carcinogenicity study. The second study thus provided no evidence that zidovudine acts as a transplacental carcinogen.</p><p>It is concluded that the transplacental carcinogenicity data from the first study represents a hypothetical risk, whereas the reduction in risk of maternal transfection of HIV to the uninfected child by the use of zidovudine in pregnancy has been well proven.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Reproductive toxicology</strong></p><p><strong><em>&nbsp;</em></strong>Studies in pregnant rats and rabbits with zidovudine have shown increased incidences of early embryo deaths. A separate study in rats found that dosages very near the oral median lethal dose caused an increase in the incidence of foetal malformations. No evidence of teratogenicity has been observed at lower dosages tested.</p><p>Fertility: Zidovudine did not impair male or female fertility in studies in rats.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>RETROVIR Capsule shell:</em></strong><br />titanium dioxide, gelatin, black iron oxide.</p><p><strong><em>RETROVIR Capsule contents</em>: </strong><br />starches, microcrystalline cellulose, sodium starch glycollate, magnesium stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The expiry date is indicated on the packaging.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Keep<em> RETROVIR</em> capsules (100 mg) dry and protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>RETROVIR</em> capsules 100 mg:</p><p>PVC/aluminium foil blister pack, amber glass bottle with polyethylene snap fit closure, or HDPE bottle with child resistant/tamper evident closure.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special instructions are required.</p><p>&nbsp;</p><p>Not all presentations are available in every country.</p><p>&nbsp;</p><p><strong><em>RETROVIR</em></strong> is trademark owned by or licensed to the ViiV Healthcare group of companies.<!--[if supportFields]><span
style='font-size:11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:
major-bidi;mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE vault_nd_48fe7cb0-372c-454f-9dbf-6d01d74fc568
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:
major-bidi;mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>&copy;2023 ViiV Healthcare group of companies. All rights reserved<!--[if supportFields]><span
style='font-size:11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:
major-bidi;mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_7088cb79-9d06-4fb4-b3ca-214c74dd0a53 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:
major-bidi;mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured and packed by: 
Delpharm Poznań Spółka Akcyjna, ul. Grunwaldzka 189, 60-322 Poznań, Poland 

Marketing Authorisation Holder: 
Glaxo Saudi Arabia Ltd.* Jeddah, KSA.
Address: P.O. Box 22617 Jeddah 21416 – Kingdom of Saudi Arabia.
*member of the GlaxoSmithKline group of companies 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Version number: GDS40/IPI16
Date of issue: 27 May 2022 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>